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1. HOST DEFENSE and ANTIMICROBIAL PEPTIDES (AMPs) 
 
1.1 Host defense 
 
The immune system is composed of an innate (non-specific) and an adaptive (specific) 
response. Innate immunity is constitutively present, acts immediately following an 
infection and is termed non-specific because the protective response is the same 
regardless of the initiating factor. This is in contrast to the adaptive immune system, 
which is slower, responds specifically, and generates an immunological memory. 
The primary response of innate immunity is inflammation. Injured cells release 
cytokines and other pro-inflammatory factors (e.g., bradykinin, histamine, leukotrienes, 
prostaglandins, serotonin, etc) to control the spread of infection and promote healing. 
These pro-inflammatory mediators induce vasodilatation and attract phagocytes: 
initially neutrophils, which participate in the response by also attracting other immune 
cells. The innate response involves a wide number of cell types but is particularly 
dependent on neutrophils and macrophages (phagocytosis), and basophils and mast cells 
(inflammation). Another important function of the innate immune system is to stimulate 
the adaptive immune response via antigen presentation. 
The elements of the innate immune system are: 
o Anatomical barriers to infections. The epithelial surfaces act as first line of 
defense against invading organisms forming a physical barrier that is impermeable to 
most infectious agents. Movement due to cilia or peristalsis, the flushing action of tears 
and saliva, and the trapping effect of mucus help prevent microbial colonization of 
different organs. 
o Humoral components. Once infectious agents have penetrated tissues, 
humoral factors play an important role in inflammation. These factors are found in 
plasma and at the site of infection. They include: i) the complement system, which once 
activated can lead to increased vascular permeability, recruitment of phagocytic cells, 
and opsonization and lysis of bacteria; ii) the coagulation system, which contributes to 
the increased vascular permeability; in addition, some of its products act as chemotactic 
agents for phagocytic cells or as antimicrobial molecules (e.g., the beta-lysin protein 
that is produced by platelets during coagulation); iii) other molecules, such as 
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lactoferrin, transferrin, interferons, lysozyme, cytokines, lactic and fatty acids and 
antimicrobial peptides (AMPs). 
o Cellular components. The main cell lines of defense involved in the non-
specific innate response are dendritic cells, monocytes, macrophages, granulocytes, and 
natural killer cells, as well as the skin, pulmonary and gut epithelial cells that form the 
interface between an organism and its environment.   
Among the innate immune components, this PhD thesis will focus on the role of 
antimicrobial peptides and macrophages during bacterial infections. 
 
1.1.1 Macrophages  
 
These cells are important elements of immune defence due to their capacity to 
phagocytose foreign material, to produce cytokines and to present antigens to T cells 
(Gordon and Taylor 2005). 
Macrophages derive from blood monocytes by maturation upon migration from the 
capillary bed to tissue sites, where they are exposed to environmental signals. 
Macrophages are more numerous than circulating monocytes due to their long life span, 
which can last from several weeks to years (van Furth and van Dissel 1989). They can 
be found in many tissues, including connective tissue, liver, lung, lymph nodes, spleen, 
bone marrow, serous fluids, skin, pleural and alveolar cavities. Local populations of 
macrophages are maintained by proliferation of resident progenitor cells and influx of 
monocytes from blood. Traditionally, macrophages have been described as antigen-
presenting phagocytes that secrete pro-inflammatory and antimicrobial mediators 
(Gordon  1999).
 
 
Mounting evidence, however, describes a more complex model involving multiple 
macrophage phenotypes carrying out different functions and eliciting divergent effects 
on surrounding cells and tissues (Hallam et al. 2009).
  
Classically, the activation of macrophages requires a priming signal in the form of IFN-
gamma via the IFN-gamma receptors. When the primed macrophage subsequently 
encounters an appropriate stimulus, such as bacterial LPS, it becomes classically 
activated (Krutzik et al. 2005) and exhibits a Th1-like phenotype, promoting 
inflammation, extracellular matrix (ECM) destruction, and apoptosis. Alternatively, 
activated macrophages do not require any priming. IL-4 and/or IL-13 can act as 
sufficient stimuli (Stein et al. 1992; Doherty et al. 1993). The binding of these factors to 
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their respective receptors is followed by fluid-phase pinocytosis of soluble antigen 
(Brombacher 2000; Conner and Schmid 2003). The internalized soluble antigen is then 
loaded onto MHC class II and subsequently presented to T cells.
 
Alternatively, activated 
macrophages display a Th2-like phenotype, promoting ECM construction, cell 
proliferation, and angiogenesis. 
In vitro maturation of monocytes to macrophages is induced by serum factors or 
artificial stimuli such as phorbol-12-myristate-13-acetate (PMA), a potent tumor 
promoter, and colony stimulating factor (CSF), a glycoprotein that binds specific 
receptors and activates intracellular pathways of proliferation and differentiation. These 
processes are accompanied by a characteristic change in the secretory repertoire of 
macrophages and typical morphological and biochemical transformation. They are 
larger than monocytes because of their abundant cytoplasm, and the nuclear chromatin 
appears looser. Macrophages also show an increased number of cytoplasmic organelles, 
but the content of lysosomes may vary with the stage of cellular maturation, as well as 
with location and activity of the cells. Macrophages are metabolically and functionally 
more active than monocytes, showing an increase in protein content, glucose utilization, 
pinocytic and phagocytic activities and synthesis of enzymes (Jain 1993). 
 
1.1.2 Phagocytosis 
 
Phagocytosis is defined as a mechanism for internalizing and destroying particles 
(Cardelli 2001). Many mammalian cells can perform phagocytosis. For example, non-
professional phagocytes contribute to clearance of apoptotic cells, which is a process 
essential in tissue homeostasis (Birge and Ucker 2008). Nevertheless, professional 
phagocytes, which include neutrophils, dendritic cells, and especially macrophages, 
play a major role during host defence since they have the ability to recognize pathogens 
via immuno-receptors on their surface. Phagocytosis is initiated by adherence of a 
particle to the surface of the plasma membrane of a phagocyte. This step usually 
involves several types of pathogen-related molecules recognized by surface receptors on 
the membrane of the phagocyte.  
Bacterial lipopolysaccharide (LPS) is known as one of the most effective inducers of 
macrophage activation. LPS is initially bound by soluble LPS binding protein (LBP) 
found in plasma and then by either soluble or membrane-bound CD14. This protein 
delivers LPS to the LPS recognition complex (Yang et al. 1999), which consists of the 
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Toll-like receptor 4 (TLR4). The TLRs are important pathogen receptors that are 
expressed on immune system-related cells and are involved in direct killing of 
pathogens, as well as in the production and/or release of pro-inflammatory cytokines, 
chemokines, cell surface markers and anti-microbial peptides by the stimulated host 
cells (Aderem and Ulevitch 2000, Takeda et al. 2003). Binding of a pathogen to a TLR 
initiates a signalling pathway that leads to the activation of a transcription factor that 
turns on cytokine genes such as those for tumor necrosis factor-alpha (TNF-α), 
interleukin-1 (IL-1), and chemotactic compounds that attract white blood cells to the 
site of infection and enhance phagocytosis.  
Pathogens are subsequently taken up into vacuoles known as phagosomes. Once inside 
the cytoplasm, these vesicles fuse with lysosomes forming a phagolysosome. The 
killing and digestion of the bacterial cell takes place in the phagolysosome as a 
consequence of the presence of different factors: degradative enzymes (proteases, 
lysozyme, glycosydases, phospholipases, and nucleases), antimicrobial cationic peptides 
from the lysosome-like granules, the acid pH, and the reactive oxygen species derived 
from activation of the NADPH oxidase, which promotes the respiratory burst event 
leading to lethal modifications of engulfed microbes. Dead microbes are rapidly 
degraded in phagolysosomes to low molecular-weight components. Macrophages digest 
debris and allow insertion of microbial antigenic components into the plasma membrane 
for presentation to lymphocytes and induction of adaptive immune responses (Fig. 1.1). 
Suitable antigens are in fact processed and loaded onto MHC class I and class II 
molecules in late endocytic compartments. The peptide-loaded MHC I complexes are 
transported to the cell surface, where they may be recognized by T-cell receptors on 
CD8 T cells. Following transport to the cell surface, peptide-loaded MHC II may be 
recognized by T-cell receptors on CD4 T cells.  
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Fig. 1.1 Phagocytosis by a macrophage. A bacterium, which may or may not be opsonized, 
is phagocytosed and ingested in a membranous vesicle called the phagosome. Digestive 
granules (lysosomes) fuse with the phagosome, to form a structure called the phagolysosome, 
and release their contents. The killing and digestion of the bacterial cell takes place in the 
phagolysosome. The macrophage egests debris while processing the antigenic components of 
the bacterium, which return to its surface in association with the MHC II for antigen 
presentation to T cells (Todar 2008). 
 
1.2 Antimicrobial peptides (AMPs)   
 
During the immune response, antimicrobial peptides (AMPs) are expressed and released 
to limit the replication and viability of bacteria at the site of infection. Because of their 
multifunctional roles both in the innate and adaptive immunity (Yang et al. 2001), a 
new and wider definition of these peptides has been introduced: Host Defense Peptides 
(HDPs).  
AMPs are evolutionary ancient members of the host defense system. Originally 
characterized in plants and insects, AMPs have been found in all classes of organisms 
and are a widely used mechanism of biochemical defence against pathogens. Their 
emerging diverse functions in immune response are stimulating a strong interest on 
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these molecules also for the future development of multipurpose anti-infective drugs. So 
far, over 1200 AMPs have been already identified or predicted from genome 
sequencing. 
They are typically cationic and amphipathic molecules, with a relatively short length 
(less than 100 residues, mostly between 12 and 50). Based on their primary structure 
and conformation, they may be classified as: 
a. linear peptides with amphipathic -helical domains; 
b. linear peptides with extended conformations and rich in specific amino acids; 
c. -hairpin peptides stabilized by 1 or 2 disulphide bonds; 
d. -sheet structures stabilized by 3 or more disulfide bridges. 
In addition to this variety of structures, they are also expressed by a variety of 
producing cell types and, in vivo, multiple AMPs are usually co-expressed by the same 
cells during infection (Lai et al. 2009). Their expression is commonly induced by 
microbes, microbial components or inflammatory signals, and can be regulated both at 
the transcriptional and post-transcriptional levels. 
The constitutive expression of AMPs is rare and under strict developmental control and 
is influenced by age and sexual maturation. In adults, AMPs can be stored in a highly 
concentrated form within cellular granules or vesicles, and then rapidly released (Lai 
and Gallo 2009). Their release at the site of infection can involve signalling by the 
pattern recognition receptors, such as Toll-like receptors (TLRs), or be induced by 
specific cytokines.  
AMPs act against a wide spectrum of Gram-positive and Gram-negative bacteria, as 
well as fungi and some viruses. They show a multimodal mechanism of action (Fig. 2). 
In most cases they interact and disrupt membrane integrity (Shai  2002): depending on 
their amino acid composition, amphipathicity, cationic charge and size, they can cover 
the surface of the membrane in a carpet-like manner and act as a detergent upon the 
membrane bilayers (carpet model); otherwise, they can produce transient cavitation of 
the membrane (toroidal-pore model); the peptides can also associate with the lipid head 
groups even when they are perpendicularly inserted in the lipid bilayer (barrel-stave 
model). In other cases, translocated peptides can alter the cytoplasmic membrane 
septum formation and interact with intracellular targets thus inhibiting cell-wall 
synthesis, nucleic-acid and protein synthesis or enzymatic activity (Brodgen et al. 
2005). 
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Fig.1.2. The Shai-Matsuzaki-Huang model of the mechanism of action of membranolytic 
antimicrobial peptides. a. Electrostatic interaction of the peptide with the outer bacterial 
membrane. b. Integration of the peptide into the membrane and thinning of the outer leaflet. c. 
Phase transition and 'wormhole' formation. Transient pores form at this stage. d. Transport of 
the peptide into the inner leaflet. e, Diffusion of the peptide into the cytosol to reach 
intracellular targets. f. Collapse of the membrane into fragments and physical disruption of the 
target cell (Shai 2002).  
 
AMPs have also the ability to invade the barrier of the bacterial cell wall, thereby 
permitting passage of various molecules into the cells (van’t Hof et al. 2001). In 
addition to their direct antimicrobial activity, they also show an active role in the 
transition to the adaptive immune response by exerting chemotactic activity for human 
monocytes, neutrophils, and T-cells and by activating the release of different immune 
factors such as tumor necrosis factor  (TNF- ), interleukin 1 (IL-1), and interferon-  
(IFN- ) (Yang et al. 2001). Moreover, it has been found that they can also promote 
wound healing and angiogenesis. In vivo animal models indicate that host defence 
peptides are crucial for both prevention and clearance of infection. 
In mammals, AMPs have been found in the granules of phagocytes, in mucosal or skin 
secretions
 
from epithelial cells, or as the degradation products of proteins. The most 
extensively investigated families of AMPs in vertebrates are the alpha- and beta-
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defensins (Ganz and Lehrer 1998), and the cathelicidin peptides (Zanetti et al. 1995, 
Zanetti et al. 2002, Zanetti 2004). Considering the whole array of AMPs, one of the 
most intriguing groups is that of the proline-rich antimicrobial peptides, whose 
members have attracted considerable interest for their distinct mode of action, which is 
independent on membrane lysis. 
 
1.3 Proline-rich antimicrobial peptides  
 
Proline-rich antimicrobial peptides (PR-AMPs) are a group of peptides widespread in 
nature that have been found in insects (Otvos  2002), mammals (Gennaro et al. 2002),  
amphibians (Li et al. 2004), crustaceans (Destoumieux et al. 1999, Rolland et al. 2010) 
and molluscs (Gueguen et al. 2009). Although diverse in sequence, they show some 
common features: i) a high content of proline residues, ii) a net cationic charge mainly 
due to the presence of arginine residues, and iii) a mode of action that does not depend 
on membrane damage, at least at low concentrations (Scocchi et al. 2011).  
All mammalian PR-AMPs belong to the cathelicidin family. The members of this 
family are characterized by a highly conserved proregion (the cathelin domain), which 
is their hallmark. This region shares sequence identity to cathelin, a protein that was 
isolated from porcine neutrophils as an inhibitor of cathepsin L (cathelin is an acronym 
for cathepsin L inhibitor) (Kopitar et al. 1989), and which is likely the proregion of a 
cathelicidin. The cathelin-like proregion is immediately followed by a highly variable 
peptide domain, which exerts antimicrobial activity once released by proteolytic 
cleavage (Fig. 1.3). The cathelicidins are synthesized as pre-propeptides and stored 
within the cells as propeptides. The proregion likely protects the peptide from 
proteolytic degradation in a protease-rich environment (Zaiou et al. 2003) and the cell 
from the potential toxic effects of the free peptide (Scocchi et al. 1992).  
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Fig. 1.3. Schematic representation of a member of the cathelicidin family with examples of 
sequences corresponding to active cathelicidin-derived AMPs. 
 
The presence of conserved regions such as the 5’ region spanning the 5’ UTR, the 
sequence coding for the signal peptide and the propiece in the cathelicidin mRNAs, 
allowed the identification of many congeners in other species by applying the RACE 
protocol (Zanetti et al. 1995). Interestingly, the number of different cathelicidins varies 
substantially among species with one member present in humans and primates and over 
ten in pig and cattle.  
The presence of PR-AMPs in mammals has only been found in artiodactyls. The first 
two members of this group were isolated from circulating bovine neutrophils and named 
bactenecin 5 (Bac5) and 7 (Bac7) (Gennaro et al. 1989), later followed by a putative 
pseudogene containing the sequence of a third bovine PR-AMP, Bac4 (Scocchi et al. 
1998). Their orthologues have been identified in other bovids, including sheep and goat 
(Shamova et al. 1999), in addition to additional members (OABac11 and OABac6) 
detected in the former species (Huttner et al. 1998). Other types of PR-AMPs have been 
identified in pig leukocytes: PR-39, whose name derives from the high content of Pro 
(P) and Arg (R) and from a length of 39 residues (Agerberth et al. 1991), and 
prophenins (Pungercar et al. 1993).  
Despite a similar amino acid composition, and apart from the similarity of orthologues 
in evolutionarily related species, they show different length and sequences and are 
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characterized by the presence of typical, but differently repeated proline motifs, of the 
type PPRX or PRPX, where X is most often a bulky hydrophobic residue or Gly (Table 
1). Apart from cathelicidins, other proline-rich AMPs are not common in mammals. In 
fact, the only other member found is a weakly cationic peptide named basic proline-rich 
peptide or SP-B, which was isolated as the main component of porcine salivary gland 
granules (Cabras et al. 2008). This peptide has many Proline residues and possesses a 
good antifungal activity and a negligible antibacterial activity (Cabras et al. 2008). 
Numerous well-characterized PR-AMPs have been identified in insects and are divided 
into short-chain and long-chain proline-rich peptides (Bulet et al. 1999). The short-
chain peptides include drosocin, a 19-residue peptide isolated from Drosophila 
melanogaster (Bulet et al. 1993), and the apidaecins, from the lymph fluid of honeybees 
(Casteels et al. 1989) and other hymenoptera (Otvos 2002) Pyrrhocoricin, a well studied 
PR-AMP isolated from the hemypteran insect Pyrrhocoris apterus, belongs to the long-
chain proline-rich peptides (Cociancich et al. 1994). An interesting structural feature of 
some Pro-rich peptides of insects is the presence of an O-glycosidic substitution at the 
level of a conserved, centrally located threonine residue, which is relevant for the 
antimicrobial activity. PR-AMPs were also found in invertebrates other than insects, 
such as crabs (Schnapp et al. 1996) and shrimps (Destoumieux et al. 2000). 
Concerning the antimicrobial activity of mammalian PR-AMPs, this was tested against 
a wide panel of Gram-negative and Gram-positive species. These peptides are active in 
the micromolar range of concentration and the most common susceptible 
microorganisms are the Enterobacteriaceae (e.g., Escherichia coli, Salmonella 
typhimurium, Enterobacter cloacae and Klebsiella pneumoniae) (Skerlavaj et al. 1989, 
Shi et al. 1996, Shamova et al. 1999). The activity of these peptides decreases by 
increasing the salt concentration in the medium and by lowering the pH to acidic values. 
PR-AMPs from insects are also active against Gram-negative bacteria, with only a few 
Gram-positive species that are affected (Casteels et al. 1989). 
 
1.3.1  Mode of action of PR-rich peptides 
 
The PR-AMPs thus far identified are all characterized by a non lytic mechanism of 
action that explains their slow killing kinetics (from several minutes to some hours) 
compared to lytic AMPs, which generally are fast acting compounds (they kill 
susceptible bacteria within few minutes upon exposure).  
The relevance of peptide stereochemistry for the antimicrobial activity supports the 
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hypothesis that they act by a mechanism different from that of lytic peptides. In fact, at 
variance with the all-D enantiomers of these latter AMPs, which display the same 
activity of the all-L counterparts, indicating a non-stereospecific mode of interaction 
with the bacterial membranes (Wade et al. 1990; Bassell et al. 1990), the all-D 
enantiomers of PR-AMPs show in general a marked loss of activity (Podda et al. 2006; 
Otvos 2002; Casteels et al. 1994), indicating that at least one step in their mechanism is 
stereospecific. Interestingly, it has been shown for both mammalian and insect PR-
AMPs that they have the ability to penetrate into bacterial cytoplasm without any 
apparent membrane damage (Podda et al. 2006) and that this step is necessary to exert 
their microbicidal activity, at least at about the MIC concentrations. In addition, the 
peptides’ uptake into bacterial cells appears to be energy-dependent and to involve a 
permease/transporter-mediated process (see below) (Mattiuzzo et al. 2007; Benincasa et 
al. 2009). All these results suggest that the PR-AMPs act by interacting with one or 
more intracellular targets and inhibiting their activity. 
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1.3.2  Intracellular bacterial killing. 
 
Until now, few intracellular bacterial processes have been identified with which PR-
AMPs interfere. One of the killing mechanisms observed for AMPs such as PR-39 
(Boman et al., 1993) and indolicidin (Subbalakshmi and Sitaram, 1998) is the inhibition 
of cell division, which may be the consequence of DNA, RNA and/or protein synthesis 
inhibition.  
Disruption of respiratory mechanisms leading to the generation of reactive oxygen 
species is another killing mechanism, employed by histatins against fungi (Bellomio et 
al. 2007). Another significant antibacterial mechanism common to different Pro-rich 
peptides, such as drosocin, pyrrhocoricin, apidaecin (Otvos 2000), and Bac7 (Scocchi et 
al. 2009) is the inhibition of the chaperone protein DnaK. 
This chaperone assists a large variety of protein folding processes, so that the 
inactivation of susceptible bacteria by insect and mammalian PR-AMPs may depend on 
their ability to inhibit protein folding and refolding by binding to this protein. However, 
it has been reported, at least for Bac7, that its in vitro interaction with DnaK does not 
translate into an altered susceptibility of a dnaK-knock out strain of E. coli (Scocchi et 
al., 2009), suggesting that other internal targets involved in bacterial killing are present 
and have still to be identified. 
 
1.3.3  Additional biological activities of PR-AMPs peptides 
 
Some PR-AMPs exert other biological activities in addition to bacterial inactivation. In 
fact, they can modulate innate immune responses and boost processes that resolve 
infection by directly interacting with cells of the innate immune system (monocytes, 
dendritic cells, T-cells, epithelial cells) or by influencing the bioactivities of such cells 
in an indirect manner (Bowdish et al. 2006; Brown and Hancock 2006). For example, it 
has been shown that PR-39 modulates angiogenesis (Li et al. 2000) and wound healing 
(Heilborn et al. 2003), and displays chemotactic activity (Eilsbach 2003; Yang et al. 
2004; Beisswenger 2005). Moreover, it also shows efficacy in limiting myocardial 
damage after experimental ischemia in rodent models (Hoffmeyer et al. 2000).  
Among the PR-AMPs, the one used in the experiments reported in this PhD thesis is the 
N-terminal fragment 1-35 [Bac7(1-35)] of the cathelicidin-derived peptide bactenecin 7 
(Bac7), isolated from bovine neutrophils (Gennaro et al. 1989).  
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1.4  Bactenecin 7 
 
The bactenecins Bac7 and Bac5 were isolated from bovine neutrophils over twenty 
years ago (Gennaro et al. 1989) and played a major role in the elucidation of their 
biosynthesis and maturation (Zanetti et al.1990).   
Bac7 is a cationic 60-residue peptide characterized by an Arg-rich cationic N-terminal 
region followed by three identical hydrophobic tandem repeats of 14 residues (Fig. 1.4).  
 
 
 
Fig. 1.4. Schematic representation of Bac7 sequence 
 
It exerts in vitro a potent bactericidal activity against several Gram-negative species 
such as E. coli, S. typhimurium, K. pneumoniae, and E. cloacae at concentrations from 1 
to 10 M (Gennaro et al. 1989). It also arrests the growth of some strains of 
Pseudomonas aeruginosa and is active against a panel of Gram-negative, antibiotic-
resistant clinical isolates (Table 2) (Benincasa et al. 2004). In addition, it neutralizes the 
human herpes simplex virus (Zerial et al. 1987).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 mammals 
 Bactenecin  
 
Indolicidin  
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Table 2 Antibacterial activity of the Bac7 fragments Bac7(1-35) and Bac7(1-16) against 
Gram-negative clinical isolates. MIC value is expressed in M. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bac7 is synthesized as pre-propeptide by neutrophil precursors in the bone marrow. 
After removal of the signal sequence, the proBac7 form is stored in the large granules of 
the bovine neutrophils and the active antimicrobial peptide is released upon proteolytic 
cleavage by elastase, which is stored in the azurophil granules (Scocchi et al. 1992). 
This event occurs when the contents of both large granules and azurophils are 
discharged into the phagosome after phagocytosis by neutrophils (Zanetti et al. 1990, 
Scocchi et al. 1992).  
Previous structure-activity relationship (SAR) studies with chemically synthesized 
fragments of Bac7 from 13 to 35 residues in length and covering the whole sequence of 
the peptide, have shown that the fragment Bac7(1–35) maintained an antibacterial 
activity comparable to that of the native peptide. In addition, these investigations 
showed that the N-terminal part of the peptide is necessary for activity, as indicated by 
the severe decrease in antibacterial activity upon removal of the first four N-terminal 
residues (RRIR), and that a minimum length of 16 N-terminal residues is required for 
biological activity (Fig 1.5) (Benincasa et al. 2004). 
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Fig.1.5. SAR studies: antibacterial activity of different Bac7 fragments. 
 
Due to its positive charge, Bac7 interacts electrostatically with the lipid bilayer of the 
outer membrane of Gram-negative bacteria. After this event, it may inactivate the target 
cell via two different modes of action, depending on its concentration: i) at near-MIC 
concentrations it acts via a mechanism based on a stereospecific and energy-dependent 
uptake that is likely followed by its binding to unknown intracellular targets; ii) at 
concentrations several times the MIC value, the peptide acts via a non-stereoselective, 
membranolytic mechanism common to most of the AMPs (Podda et al. 2006). 
A putative membrane interactor of the N-terminal Bac7(1-35) active fragment has been 
described in E. coli. This interactor is SbmA, an inner membrane protein responsible for 
the uptake of the peptide into the bacterial cells. In fact, mutations affecting the sbmA 
gene lead to a partial resistance of E. coli and S. typhimurium strains to Bac7(1-35) and 
to other proline-rich peptides (Mattiuzzo et al. 2007, Prantig et al. 2008). 
Bac7 is also able to interact with mammalian cells and to affect cellular functions. It has 
been demonstrated that Bac7(1-35) is rapidly internalized by cells mainly via 
macropinocytosis and, in part, via direct translocation across the plasma membrane 
(Tomasinsig et al. 2006) without cytotoxic effects up to a concentration of 50 M. Once 
inside the cell, the peptide was detected in the cytoplasm as well as in the nucleoli. The 
uptake process is energy-dependent and temperature-sensitive and, also in this case, the 
first four N-terminal amino acids are essential for Bac7(1-35) internalization. Focusing 
on its biological effects on eukaryotic cells, the peptide stimulates DNA synthesis and 
proliferation of fibroblasts (Tomasinsig et al. 2006).  
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2.  IN VIVO THERAPEUTIC POTENTIAL OF AMPs  
 
2.1  In vivo applications of AMPs 
 
The spread of antibiotic-resistant bacterial strains is driving researchers and pharma 
industry to find new treatment options for infective diseases. As a potential new class of 
antibiotics, AMPs combine several attractive intrinsic properties that make them good 
candidates for the development of antibacterial drugs, although coupled to weaknesses, 
such as poor pharmacokinetics, susceptibility to proteases and high production costs. 
Their broad spectrum of activity and their reduced propensity to select resistant strains 
are however of particular clinical significance, and this features induced many groups to 
investigate the in vivo efficacy of AMPs. 
For example, PR-39, at a dose of 40 mg/kg, significantly improved animal survival 
when tested in a septic shock mouse model induced by LPS (Mahdani et al. 2002, 
James et al. 2003).  
The efficacy of the human LL-37 peptide was widely investigated in different animal 
models of infection. In rat models of Gram-negative sepsis induced by E. coli, it 
significantly decreased the plasma levels of endotoxin and cytokines as well as the 
bacterial load (Cirioni et al. 2006). The positive protective effects of LL-37 and of its 
mice orthologue CRAMP were also proved when the peptides were endogenously 
expressed in a mouse model of urinary E. coli infection and in human mucosal 
immunity of the urinary tract (Chromek et al. 2006). The efficacy of the human peptide 
was also demonstrated in a Candida albicans skin infection mouse model (Lopez-
Garcìa et al. 2005). Finally, it was demonstrated that topically added LL-37 strongly 
accelerated delayed-excision wound closure in mice, further supporting the therapeutic 
potential of the peptide in the promotion of wound healing in a mouse model of type II 
diabetes (Carretero et al. 2008).  
The therapeutic efficacy of Bac7 as an antiendotoxic compound was investigated in a 
rat model of Gram-negative septic shock. Treatment of the animals with 1 mg/kg of the 
active fragment Bac7(1-35) resulted in a significant decrease in plasma endotoxin levels 
and greatly improved survival (Ghiselli et al. 2003). 
The potent and broad spectrum antimicrobial activity of SMAP-29, an -helical 
cathelicidin with a lytic mechanism, and its ability to protect animals from infection led 
to a conspicuous number of studies aimed at assessing its potential as a novel anti-
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infective agent. Clear evidence for host defence capacity of SMAP- 29 was obtained in 
a lamb pneumonia model of a bovine respiratory disease associated with Mannheimia 
haemolytica, in which intra-tracheal administration of this ovine peptide at the 
concentration of 37 mg/Kg, significatly reduced the bacterial concentration in the 
bronchoalveolar fluid and in consolidated pulmonary tissues, as well as the severity of 
the lung lesions (Brogden et al. 2001).  
Efficacy studies, in a rat model of staphylococcal device-related infection, were 
performed using the bovine cathelicidin peptide BMAP-28. Catheters pre-treated with 
this peptide showed a drastic reduction in their development of bacterial biofilms 
(Cirioni et al. 2006). The therapeutic potential of BMAP-28 and of its inversed (D) and 
retro-inversed (RI) isomers was also tested in a mouse model of peritoneal infection and 
each peptide conferred protection at the dose of 20 mg/kg, significantly reducing the 
bacterial load (Kindrachuk et al. 2010). 
A promising aspect in improving antimicrobial therapy is the combination of 
conventional antibiotics with AMPs. To mention a few examples, the application of the 
frog peptide temporin L (1 mg/kg) from Rana temporaria, combined with -lactams in 
a murine model of Gram-negative sepsis, led to a lower plasma endotoxin level and to a 
higher antimicrobial activity , which resulted in an improved survival rate (Giacometti 
et al. 2006); Similarly, the combination of two -helical AMPs (cecropin A and 
magainin II) and vancomycin resulted effective against S. aureus in a murine sepsis 
model (Cirioni et al. 2006). Numerous clinical trials have been also applied to many 
AMPs. 
 
2.2  Clinical trials and applications of AMPs 
 
Antimicrobial peptides are currently in clinical use for disease treatment as well as 
prophylactically, to prevent infections in neutropenic or cystic fibrosis patients (Marr et 
al. 2006). Colomycin, a derivative of polymyxin, is used systemically in intravenous 
therapy of lung infections in cystic fibrosis patients (Li et al. 2006). Topical 
applications of polymyxins and gramicidin S are safely used in the treatment of 
infections caused by P. aeruginosa and A. baumannii and often associated with 
bacitracin for generic wound creams, eye drops and ear drops (Marr et al. 2006).  
Currently, the starting point for development of new drugs is the identification of 
natural antimicrobial peptides followed by their modification and optimization. A few 
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of these “new generation” AMPs, which differ from their natural progenitor by a limited 
number residues, are currently undergoing clinical trials. For instance, P-113, a 
derivative of histatin 5, a human salivary peptide, was reported for HIV patients with 
oral candidiasis. The benefits of P-113 over current treatments are its safety profile, 
which has been demonstrated in previously conducted clinical trials, and the reduced 
risk of drug resistance due to its unique mechanism of action (Helmerhorst 2007). A 
peptide derived from bovine indolicidin, MX-226, developed by Migenix, is currently 
under confirmatory Phase III study for the treatment and prevention of catheter-
associated infections, under a special protocol assessment with the FDA. The most 
promising candidate is omiganan, an indolicidin analogue, used in preventing catheter 
related bloodstream infections and various cutaneous infections (Fritsche et al. 2008; 
Sader et al., 2004). This peptide is now awaiting registration. 
Finally, the lantibiotic nisin was developed commercially by Astra and Merck for 
treatment of gastric helicobacter infections and ulcers, while other nisin variants (nisin-
A and Z) have entered preclinical trials for treating vancomycin-resistant enterococci. 
(Field 2010). 
 
2.3 Improvement of AMPs as therapeutic agents  
 
As observed above, AMPs possess features that make them good candidates for 
development of antibacterial therapeutics. However, there are issues yet to be solved to 
pursue therapeutic implementation of the antimicrobial peptides. 
One of the main problems related to the limited clinical use of AMPs is their weak in 
vivo stability. Strategies to prolong physiological half-life of such compounds are highly 
on demand for their clinical use. Short systemic half-life (from few minutes to few 
hours) of the AMPs is commonly due to fast renal clearance, which is related to the 
hydrophilic properties of most of these agents as well as to their small size, and/or to 
enzymatic degradation caused by proteases present in blood, liver and kidney (Reddy et 
al. 2004). 
Orally administered drugs, which are absorbed from the stomach or the intestine, are 
transported in the venous blood via the vena porta through the liver to enter systemic 
circulation. Parenterally administered drugs have to pass liver and kidney, which are 
very well supplied with blood. In the kidneys, glomerular ultrafiltration occurs and the 
overall effect of the filter is to completely pass anything less than 5-7 kDa (Werle et al. 
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2006) and to (almost) completely exclude anything greater than 70 kDa. Less and less 
of the substance will pass through the filter moving in size between the lower and upper 
limit. In the case of small molecules such Bac7(1-35) (4.2 kDa), the half-life of the 
compound can be prolonged increasing their size.  
Pegylation, the covalent coupling of polyethylene glycol (PEG) chains to drugs, is one 
of the most promising and extensively studied strategies with the goal of improving the 
pharmacokinetic properties of a potentially therapeutic agent with a short half-life 
(Pasut and Veronese 2006). 
The main advantages conferred by PEG conjugation include: (1) enhanced solubility 
and, as a consequence, an improved drug bioavailability; (2) decreased antigenicity 
leading to a lower inmmunological response by the organism; (3) reduced rates of 
kidney clearance and improvement in pharmacokinetics; (4) enhanced selective 
targeting to the site of action of the drug; (5) the possibility to form an advanced 
complex drug delivery system, which, in addition to drug and polymer carrier, may 
include several other active components that enhance the specific activity of the main 
drug (Khandare et al. 2005). 
A large number of scientific articles have already been published in which the 
effectiveness of pegylation to improve half-life of drug candidates was clearly 
demonstrated (Lee et al. 2005; Ramon et al. 2005; Kozlowsky et al. 2001). 
As for stability of AMPs in biological fluids, enzymatic degradation has to be taken into 
account. A broad variety of peptidases and proteases occur in the blood and in tissues. 
Aminopeptidases cleave peptides at the N-terminus whereas carboxypeptidases cleave 
them from the C-terminal site. Endopeptidases often exhibit narrow cleavage specificity 
(Werle and Bernkop-Schnurch 2006). Methods successfully verified and now routinely 
used to improve resistance of peptides to proteases involve the modification of their N- 
and C-termini by acetylation and amidation, respectively, and/or the replacement of 
amino acids at predicted cleavage sites with other amino acids or non-natural residues 
(e.g., D-amino acids) (Stromstedt et al. 2009).  
Protease resistance can also be achieved by “head to tail” cyclization of peptides via 
bond formation between the N- and C-termini (Rosengreen et al. 2004; Dathe et al. 
2004). This type of modification has been shown to improve the stability of human 
kallikrein-2-specific peptide in human plasma for up to 24 h compared to the 4 h of the 
linear form. (Pakkala 2007). Synthetic cyclic peptides not only have favourable in vitro 
and in vivo stability profiles, but also show a greater selectivity for bacterial rather than 
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mammalian cells (Dartois et al. 2005; Oren and Shai 2000). A new, promising strategy 
that confers resistance to proteolysis (Falciani et al. 2007; Pini et al. 2007; Bracci et al. 
2003), in addition to decreased cytotoxicity (Kolar et al. 2010) and increased 
antimicrobial activity (Liu et al. 2006), is also represented by the synthesis of peptides 
in the form of dendrimers.  
Finally, also in this context, pegylation is an efficient strategy to improve peptide 
stability, especially in the case of multi-branched PEG use, where the PEG chains are 
able to “hide” the peptide sequence to the activity of proteases (Veronese and Mero 
2008). 
A strategy to improve the availability of AMPs is their conjugation to an efficient slow 
release drug delivery system, which may reduce the need for extensive modifications. 
Liposomal systems offer a number of benefits including increased circulation time of 
the encapsulated therapeutic. These systems have been widely investigated for delivery 
of anticancer drugs, while the liposome encapsulation of peptides is still under 
development. Cationic, cell-penetrating peptides have also been extensively studied for 
the delivery of molecules to intracellular compartments (Vives et al. 2008). However, 
despite being able to deliver a variety of molecule types in vitro, their in vivo 
application requires further development. Recently, the use of microspheres composed 
of polymers that allow controlled release of their cargo at specific physiological 
conditions (e.g., temperature and pH), led to promising results (Fogueri and Singh 
2009). 
In summary, physical-chemical modifications are likely required to widen the 
pharmacokinetic properties of an AMP to make it more effective in vivo. Due to the 
increased interest of researchers in this field, the therapeutic application of AMPs is 
likely to expand to include novel peptides and peptidomimetics and a wider range of 
infections. 
 
3.  SALMONELLA ENTERICA INFECTION 
 
Salmonella enterica is a facultative intracellular Gram-negative species that causes a 
wide array of diseases in a multitude of hosts. It is a facultative anaerobic bacterium that 
belongs to the family of Enterobacteriaceae and is made up of nonspore-forming rods, 
usually motile with peritrichous flagella (Warrell et al. 2003). 
The genus Salmonella contains over 2,000 sero-species and is one of the most important 
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pathogens in the Enterobacteriaceae family. Taxonomically, all strains of Salmonella 
fall within one species, S. enterica. The Typhimurium is among the most common 
Salmonella serovars causing salmonellosis in humans. In mice, S. typhimurium causes a 
systemic disease and provides a murine model for human typhoid fever that allowed 
investigating the various aspects of host-pathogen interaction in S. enterica infection 
(Santos et al. 2003). Typhoid fever disease is an important example of a severe systemic 
disease responsible for approximately 21 million cases per year worldwide (Crump et 
al. 2004). Typhoid fever disease occurs when Salmonella escapes the host immune 
defence and disseminates in different organs (Watson el al. 2010). In fact, as a 
facultative intracellular pathogen, Salmonella enterica serovar Typhimurium is able to 
invade and replicate inside a variety of phagocytic and non-phagocytic cells in vivo. 
Following intestinal colonization, salmonellae enter enterocytes, M cells and dendritic 
cells (DCs) in the intestinal epithelium. Afterwards, they reach the submucosa and can 
be internalized by resident macrophages and rapidly disseminate through the blood 
stream, accumulating in mesenteric lymph nodes and finally in liver and spleen 
(Salcedo et al. 2001) (Fig. 3.1).  
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.1. Dissemination of Salmonella from the intestinal lumen to extra-intestinal sites in 
mouse.  
 
(1) After reaching the distal ileum, the majority of Salmonellae invade M cells that overlie 
Peyer’s patches (PPs). (2–4) Most bacteria are likely to reach the mesenteric lymph nodes 
(MLN) by carriage within DCs via the lymphatic system. DCs transport Salmonella from the 
PPs (2), intestinal lumen (3) or lamina propria (LP) (4). (5) It is possible that Salmonella can be 
transported directly from the PPs to the liver and spleen, but large numbers of bacteria are 
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unlikely to migrate out of the MLN (6). (7) Salmonella can also be carried directly from the 
intestine to the liver and spleen via a hematogenous route involving carriage within CD18
+
 
phagocytes, most likely monocytes or DCs. (8) After prolonged infection, Salmonella can be 
transported between organs via the bloodstream. (9) Bile excretion from the liver also carries 
bacteria to the gall bladder. (10) Gall bladder colonization presumably leads to re-infection of 
the intestine through bile secretion (Watson et al. 2010). 
 
The ability of salmonellae to survive in a variety of host cells is essential to its virulence 
and depends, at least in part, on mechanisms of resistance to AMPs. Genetic studies 
have led to the identification of a large number of genes necessary for intracellular 
survival, and among them, the phoP/Q genes have great relevance. They encode a two-
component regulatory system, which regulates the expression of over 40 genes (Miller 
and Mekalanos 1990) and are also involved in resistance to AMPs (Gunn and Miller 
1996). PhoQ is an inner membrane sensor kinase with a periplasmic domain that is 
responsible for sensing specific signals in the environment, and a cytoplasmic domain 
responsible for intermolecular autophosphorilation upon activation and subsequent 
phoshotransfer to PhoP. PhoP is a regulator protein involved in the activation of the 
expression of important virulence genes. Most of them are clustered at specific sites of 
the Salmonella chromosome called pathogenicity islands (SPI). Two SPIs are important 
for virulence of Salmonella, SPI-1 and SPI-2. Both encode two different type III 
secretion systems (T3SSs), needle-like structures on the bacterial surface. T3SSs are 
used by many Gram-negative pathogens to deliver bacterial effector proteins into host 
cells (Hueck 1998) through formation of pores in host cell membranes (Blocker et al. 
1999). The T3SS encoded in Salmonella SPI-1 mediates the internalization of 
Salmonella into host cells by translocating inside them effector factors that induce 
membrane ruffling and cytoskeleton rearrangement in order to force Salmonella 
internalization (Schaible et al. 2010; Ibarra et al. 2009).  
Inside eukaryotic cells, T3SS1 effectors are implicated in the biogenesis of Salmonella-
containing vacuoles (SCVs), niches in which Salmonella replicates and protects itself 
from host cell antimicrobial activities (Buchmeier et al. 1991; Rathman et al. 1997; 
Vazquez-Torres et al. 2000) (Fig. 3.2). After the early stages of infection, the SPI-1 
system is down-regulated (Drecktrah et al. 2005; Ericksson et al. 2003), and the 
expression of the SPI-2 T3SS is induced, mainly due to the acidic conditions present 
inside the SCVs (Coombes et al. 2004). The effector proteins translocated by the T3SS-
2 system are necessary to continue modification of the SCV, allow intracellular 
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bacterial growth and finally induce host cells to apoptosis (Monack et al. 1996; Hersch 
et al. 1999). SPI-2, with its T3SS-2, is especially involved in Salmonella survival into 
macrophages. In this scenario, bacteria are chosen by a professional phagocyte which is 
duly programmed to eliminate them. Under this condition, SPI-2 appears to prevent the 
phagocyte NADPH oxidase from trafficking toward SCVs, both reducing the oxidant 
stress encountered by bacterial cells and potentially enhancing collateral oxidative 
damage to host tissues (Vazques-Torres et al. 2000). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.2. Salmonella internalization into host cells. Once internalized, Salmonella cells are 
located in vacuoles (SCV). As a consequence, the SCV becomes fusogenic with 
lysosomal/late endosomal compartments. This fusion allows acidification, SPI-2 effector 
induction and Salmonella-induced filament (SIF) formation. The result is an appropriate niche 
for Salmonella replication (Gutierrez et al. 2010).  
In addition to its ability to invade and replicate inside host cells, a large subpopulation 
of intracellular Salmonellae in splenic macrophages was surprisingly found to persist 
for long periods of time without undergoing a single division. Further characterization 
of these bacterial cells revealed a gradual loss in metabolic activity that appeared to be 
triggered soon after uptake by macrophages and was not influenced by the bactericidal 
activities of the host cell. This suggested entry into a dormant state; it is possible that 
these bacteria represent a reservoir that persists in chronic infections. Other potential 
reservoirs have also been proposed, such as the mesenteric lymph nodes (MLN) 
(Monack et al. 2004), the liver (Nath et al. 2010) and the gall bladder (Sinnott et al. 
1987), perhaps by forming biofilms on existing gallstones (Crawford et al. 2010).
   
  
 Aim of 
  the PhD project 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 36  
The rapid increase in the number of bacterial strains resistant to conventional antibiotics 
is a serious threat to public health. For this reason, the development of novel antibiotics 
with a mechanism of action different from that of the antibiotics in use is in high 
demand by clinicians. In this respect, AMPs are increasingly recognized as potential 
candidates for the development of new classes of antimicrobial drugs. 
They combine several attractive intrinsic properties, such as direct killing of invading 
pathogens, modulation of the immune response and, last but not least, a poor propensity 
to induce microbial resistance. In addition, successful preclinical studies with AMPs 
indicate that clinical evaluation of these agents is worth doing. 
The encouraging in vitro results already obtained with Bac7(1-35), a fragment of the 
bovine cathelicidin Bac7, its activity against Gram-negative bacteria of clinical 
relevance, its peculiar mode of action, and its low toxic effects, suggested us to test its 
in vivo therapeutic efficacy, to ascertain its potential as a lead compound for the 
development of new antimicrobial agents.  
In this context, the experiments carried out for this PhD thesis aimed at extending the 
preclinical studies thus far performed with the peptide and exploiting its therapeutic 
potential. In short, the studies performed had the scope to test: 
i) the peptide’s activity and stability in vitro in the presence of biological 
components that mimic the in vivo environment; both murine and human serum and 
plasma were used so as to compare the potential of Bac7(1-35) in different organisms; 
ii) the in vivo efficacy of the peptide in a murine model of infection: a mouse 
model of S. enterica infection resembling typhoid fever in humans was developed to 
investigate the in vivo activity of Bac7(1-35);  
iii) modifications of the peptide aimed at improving its pharmacokinetic 
properties; to this aim, several different pegylation strategies have been set up to 
optimize Bac7(1-35) bioavailability; 
iv) the effects of the peptide on cells of the human immune system involved in S. 
enterica infection, such as macrophages; these studies were designed to investigate the 
effects of Bac7(1-35) on the phagocytosis process and, once extracellularly added, its 
antimicrobial activity against pathogens that proliferate inside the macrophages, such as 
S. enterica. 
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1 . SYNTHESIS AND LABELING of BAC7(1-35) 
 
1.1 Synthesis and purification of Bac7(1-35) 
The N-terminal fragment 1-35 of Bac7 was synthesized by the solid phase on a CEM 
Liberty microwave-assisted peptide synthesizer using a 2-Chlorotrityl chloride resin 
(substitution 0.20-0.25 meq/g). Loading of the first amino acid was carried out 
manually. 
On synthesis completion, the peptide was cleaved from the resin by incubation for 4 h 
on a shaker in the following mixture: 87% trifluoroacetic acid (TFA), 8% 3,6-dioxa-1,8-
octane-dithiol (DODT), 2% triisopropylsilane (TIPS), 3% water. The cleaved peptide 
was washed several times with tert-butyl methyl ether (TMBE) and dried with N2. 
The crude peptide was then purified using a preparative C18 RP-HPLC column (Waters 
Delta-Pak
TM
 C18, 5 m, 300 Å, 25 x 100 mm). The quality of the peptide was checked 
by mass spectrometry (ESI-MS Bruker Esquire 4000) after purification. 
All the peptide solutions used in the assays described below were prepared from a stock 
solution of the purified peptide dissolved in water. The peptide concentration was 
determined by at least three methods: 
I.  by weighing the peptide used to prepare the solution; 
II. by using the Waddell method (Waddell 1956);  
III. by considering the excinction coefficients ( 215) of Gly and Pro residues and of 
the peptide bonds (Kuipers  and Gruppen 2007). 
 
1.2 Fluorescent labelling of Bac7(1-35) 
In order to fluorescently-label Bac7(1-35) via linkage of the thiol-reactive dye, ALEXA 
FLUOR
 
680 C2maleimide or BODIPY C2maleimide, a C-terminal cysteine residue 
was specifically added. Labelling of Bac7(1-35) was performed in solution with the 
purified peptide and not directly on resin because the dye is not stable under the 
peptide’s cleavage conditions (acidic pH of the trifluoroacetic acid solution). 
To label Bac7(1-35) with the ALEXA FLUOR 680, 1 mg of the fluorescent dye, was 
dissolved in 100 l of DMSO, and added dropwise to 30 ml of 10 mM Na-phosphate 
buffer, pH 7, under nitrogen bubbling in the dark. Four milligrams of Bac7(1-35)-Cys 
were then dissolved in this solution; after 1 h incubation at room temperature with 
stirring, a new 4 mg aliquot of peptide was added and the solution was left overnight at 
4°C. At the end of the incubation time, an excess of cysteine (10 mg) was added to 
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scavenge the excess of thiol-reactive reagent. The solution was left with stirring for 1-2 
h and the labelled peptide was then purified with semi-preparative RP-HPLC (Waters 
Delta-Pak
TM
 C18, 5 m, 10 x 100 mm) and analyzed by ESI-MS. The fraction 
containing the pure Bac7(1-35)-Cys36ALEXA FLUOR  680 was lyophilized and the 
concentration determined using the above mentioned methods. To label Bac7(1-35) 
with BODIPY C2 maleimide, a 20 ml peptide solution (0.1 mg/ml in 30% AcCN in 10 
mM Na-phosphate buffer, pH 8) was used with a 10-fold excess of the fluorescent dye 
(2mg in 2 ml AcCN) added drop wise under nitrogen bubbling in the dark. After 2-3 h 
of incubation at room temperature under stirring, a new aliquot of 2 mg peptide was 
added to the same solution and incubated overnight in the dark at 4 °C under stirring. 
The reaction was quenched by addition of a 10 to 20-fold excess of cysteine an 
incubated for 1 h at room temperature under stirring. The labelled peptide was then 
purified by using a semi-preparative RP-HPLC (see above), analyzed by ESI-MS and 
lyophilized. Its concentration was determined using the above mentioned methods. 
 
2. Bacterial strains 
 
Salmonella enterica serovar Typhimurium ATCC 14028 was used for the 
antibacterial assays. Salmonella enterica serovar Typhimurium LT-2 and GFP-
expressing S. typhimurium (strain LT-2) were used for the phagocytosis assays.  
 
2.1  Preparation of GFP-expressing S. typhimurium 
 
GFP-expressing bacteria were obtained by transforming S. typhimurium LT-2 with 
the pGLO plasmid carrying the inducible gfp gene under control of the arabinose 
operon and the antibiotic resistance for ampicillin. Competent cells of S. typhimurium 
were firstly prepared. In brief, a standard overnight bacterial culture in MH broth was 
prepared and refreshed the day after in 200 ml of medium, up to an OD600 of 0.5-0.7. 
The culture was transferred into four 50 ml tubes, cooled down on ice for 30 min and 
centrifuged at 1800 x g and 4°C for 15 min. After the medium was discarded, the pellet 
of bacteria was washed twice in 25 ml of sterile water and collected by centrifugation. 
The cells were resuspended in 10 ml of sterile 10% glycerol and centrifuged. Finally, 
the bacteria were resuspended in 1 ml of sterile 10% glycerol, distributed into several 
1.5 ml tubes and stored at -80°C. 
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The percentage of competent cells was verified with a test transformation with the 
pUC18 plasmid following standard methods. 
To obtain GFP-expressing bacteria, competent cells were mixed with 100 g of pGLO 
plasmid and exposed to an electric discharge (2.5 kV, 5 ms). Immediately afterwards, 
950 μl of SOC medium (20 g of bacto-tryptone, 5 g of yeast extract, 10 mM MgCl2 and 
20 mM glucose dissolved in water), and 0.5 g NaCl were added and the cell suspension 
was incubated at 37°C for 1 h. Finally, the cells were diluted and plated on MH agar 
with ampicillin (50 g/ml). Colonies were collected and prepared for storage at -80°C 
by adding 140 μl of DMSO to 1.5 ml of overnight culture in MH supplemented with 
ampicillin (50 g/ml).   
 
3. Bacterial growth conditions 
 
Mid-logarithmic phase S. typhimurium ATCC 14028 and S. typhimurium LT-2 cells 
were obtained by diluting 1:50 an overnight-grown culture, followed by incubation 
at 37°C with shaking up to an OD600 of 0,3-0,4 and diluting the suspension at the 
desired concentration. 
GFP-expressing Salmonella were grown in MH broth supplemented with ampicillin (50 
g/ml) at 37°C. After overnight incubation, an aliquot of the culture was diluted in fresh 
medium supplemented with ampicillin (50 g/ml) and the cells left to grow for 90 min 
at 37°C. Arabinose (3 mg/ml) was then added to switch on the gfp gene expression and 
the culture incubated for 2 additional hours at 37°C. At the end of the incubation time, 
the GFP-expressing S. typhimurium cells were washed and resuspended in PBS at the 
desired density. Expression of GFP was verified cytofluorimetrically. 
 
4. ANTIBACTERIAL ACTIVITY OF BAC7(1-35) IN SERUM and 
PLASMA 
 
4.1 Antibacterial activity of Bac7(1-35) in human and murine serum and 
plasma 
 
Killing kinetics assays 
The antimicrobial activity of Bac7(1-35) was first determined by performing killing 
kinetics assays against Salmonella enterica serovar Typhimurium ATCC 14028 in the 
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presence of 66% murine serum or plasma. 
Murine serum and plasma were drawn from a pool of mice. Plasma was obtained using 
2% (v/v) Na-citrate as an anticoagulant. Fluid samples were then centrifuged at 13000 g 
for 5 min and stored at -20°C until use. 
Mid-logarithmic phase S. enterica cultures were diluted in murine serum or plasma 
(66% or 25% v/v final concentration) to give approximately 1x10
6
 cells/ml, and 
incubated with 10 M Bac7(1-35) at 37 °C in a shaking water bath. Samples were 
withdrawn at different times, diluted, plated on MH agar and incubated at 37°C for 16-
18 h to allow colony counts (Podda et al. 2006). 
 
Broth microdilution susceptibility assays 
Minimum inhibitory concentration (MIC) values of Bac7(1-35) against S. typhimurium 
ATCC 14028 in the presence of 25% human and murine serum or plasma were also 
determined. 
Murine serum and plasma were prepared and stored as described above. 
Human serum and plasma were drawn from a pool of healthy donors. Plasma was 
obtained using 2% (v/v) Na-citrate as an anticoagulant. Fluid samples were then 
centrifuged at 13000 g for 5 min and stored at -20°C until use. 
The broth microdilution susceptibility assay was performed following the guidelines of 
the Clinical and Laboratory Standards Institute (CLSI 2000). 
Two-fold serial dilutions of Bac7(1-35) were prepared in 96-well microtitre plates under 
different medium conditions (human and murine serum or plasma diluted in MH broth 
to reach the final concentration of 25% and 100% MH broth as control) in a final 
volume of 50 μl. Each series included a well without peptide as a control. A total of 50 
μl of a mid-logarithmic phase S. enterica culture prepared in MH broth was added to 
each well to a final density of 5 × 10
4
 cells/ml. Samples were then incubated at 37°C for 
24 h. The MIC was taken as the lowest concentration of antimicrobial peptide resulting 
in the complete inhibition of visible growth after 24 h of incubation. 
 
4.2 Peptide stability in serum and plasma 
Western blot analysis 
To test the peptide stability in human and murine biological fluids, Bac7(1-35) (120 g) 
was incubated in 200 l of murine or human serum and plasma [25% (v/v) in PBS] at 
37°C up to, respectively,24 h and 72 h. At different times, aliquots were withdrawn, 
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diluted 1:5 in sample buffer (12% SDS, 6% dithiothreitol, 40% glycerol, 0.05% 
bromophenol blue, 150 mM Tris-HCl, pH 7), incubated for 15 min at 60°C and 
analyzed on a 16% Tricine/SDS gel. Proteins were then blotted onto nitrocellulose 
membrane and incubated overnight with shaking in 40 mM Tris-HCl, pH 7.5, 5% non-
fat milk, 0.05% Tween 20, 200 mM NaCl (blocking solution) at 4°C. Samples were 
incubated for 90 min with rabbit anti-Bac7(1-35) IgG diluted 1:1000 in blocking 
solution, followed by a HRP-conjugated anti-rabbit IgG. The ECL detection system was 
used to develop the Western blots. 
 
LC-MS analysis 
Bac7(1-35) was incubated in 250 l of human or murine serum and murine plasma 
[25% (v/v) in PBS] at 37°C for 24 h. Aliquots of 25 l (5 g of peptide) were 
withdrawn at different time intervals (0, 1, 4, 8, and 24 h) and added to 65 l of cold 
TFA (0.5% v/v) in H2O, kept on ice for 5 min and then centrifuged at 10000 x g for 5 
min. The supernatants were analysed by using an LC-ESI/MS instrument in which an 
Amersham Pharmacia Biotech HPLC is coupled to an ESQUIRE 4000 spectrometer 
(Bruker Daltonics). Components in each sample were separated by using a Jupiter C18 
analytical column [5 m, 300 Å, 2 x 150 mm (Phenomenex, USA)] with a 30 min linear 
gradient from 25 to 45% of water/acetonitrile in 0.05% TFA. The percentage of the 
intact peptide was calculated from the area of the corresponding peak in the 
chromatogram (% of intact peptide = At/A0 x 100, where At is the pea k area of the 
peptide at any given time and A0 is the peak area at time zero) (Antcheva et al. 2009).  
 
5. IN VIVO STUDIES 
 
5.1 Animals 
Male Balb/c and CBA/Ca mice of approximately 20 g and 6 weeks of age were obtained 
from Harlan Laboratories (Udine, Italy) and maintained under pathogen-free-conditions. 
All the experimental procedures were performed according to the guidelines of the 
European (86/609/EEC) and the Italian (D.L. 116/92 and subsequent addenda) laws and 
approved by the Italian Ministry of University and Research as well as by the Animal 
Experimentation Committee of the University of Trieste Animal House. 
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5.2 In vivo toxicity  
To test the toxicity of Bac7(1-35), increasing amounts of peptide dissolved in apyrogen 
PBS (0.2 ml per mouse) were injected in mice via i.p. The control animals received the 
vehicle alone. Animal behaviour and survival were monitored over a 14-day period. 
During this period mice were observed daily for signs of toxicity: their weight and the 
aspect of the hair were controlled. 
 
5.3  Salmonella infection and protective effect of Bac7(1-35) 
Inocula containing 10
2 
CFU/mouse of S. enterica ATCC 14028, expected to result in 
90-100% mortality in 4-6 days for Balb/c (Campoy et al. 2002) and 10-18 days for 
CBA/Ca, were prepared by diluting log-phase bacterial cultures in sterile PBS. Ten 
mice were infected intraperitoneally and monitored for survival over a 60-day period 
after infection. The peptide (30 mg/kg) was injected via i.p. after bacterial challenge. 
The choice of dose was based on preliminary data obtained with lower doses (data not 
shown) and on results reported in the literature for AMPs belonging to other structural 
groups. Control mice were given 0.2 ml of PBS or gentamicin (10 mg/kg). The 
experiment was repeated two times and comparable results were obtained. The analysis 
of survival curves was conducted by using the Kaplan-Meyer method and subsequent 
statistical evaluation by the Logrank test. Significance of percentage differences among 
groups was calculated by using the Fisher exact test. Values of p <0.05 were considered 
statistically significant. 
 
5.4 Viable colony counts in murine liver and spleen homogenates after 
Salmonella infection and treatment with Bac7(1-35)  
Three days after bacterial infection, a group of 3 untreated and 3 peptide-treated mice 
were killed by cervical dislocation, and the liver and spleen were removed. The organs 
were weighed, homogenized separately and dissolved in PBS. Suitable dilutions of 50 
l of the homogenate in PBS were plated in duplicate on MH agar. The plates were then 
incubated at 37°C overnight to allow colony counts. Results are expressed as number of 
CFU/g of organ. This assay was repeated twice. 
 
5.5  In vivo time-Domain Optical Imaging and Bac7(1-35) biodistribution. 
Biodistribution of Bac7(1-35) in living mice was analyzed by using the in vivo imaging 
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technology.  
 
5.5.1  Optical imaging technique 
Optical imaging is a non invasive diagnostic technology that allows visualization of 
molecular events in real-time and over time in living animals. It is increasingly used as 
a leading technology in bio-pharmaceutical research and development, both in the 
preclinical and clinical phases of research and drug development process. Traditional 
survival-based endpoints are fast going out of fashion as a way of measuring drug 
efficacy, in favour of in vivo imaging. Non-invasive mapping of cellular and molecular 
events in vivo drastically enhances the quality and quantity of information available to 
researchers, accelerating drug discovery and development and the path towards ever 
improving precocious diagnosis. This new attractive technology has been also approved 
by FDA to track drug “microdoses” in preclinical studies in order to allow 
pharmaceutical companies to enter into phase I faster. This technique is based on 
detecting the fluorescent lifetime of the fluorophore bound to the target molecule (Fig. 
1). 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. Schematic representation of the Optical imaging technique, and example of 
analysis. This technique acquires the fluorescent signal of the dye used to target the 
molecule of interest once inside a living mouse, giving information about its 
biodistribution and half-life. 
 
The lifetime is the average value of time spent by the dye in the excited state before 
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returning to the ground state and emitting a fluorescent photon (Gallant et al. 2004; 
Zhang et al. 2001). The instrument works in the Near Infrared (NIR) because of its good 
tissue penetration ( 1 cm), low absorbance and low background signal. The time 
domain technology also allows studying several biological events at the same time, 
detecting multiple fluorophores simultaneously by their lifetimes. Moreover, it is able to 
discriminate bound and unbound dyes by comparing their different fluorescence 
lifetime characteristics . 
The benefits of the fluorescence lifetime imaging system are: 
 the estimation of the relative concentration of the target molecule based on detection 
of the light intensity as a function of arrival time in nanoseconds, considering that the 
signal from deeper tissues arrives later; 
 the recognition of different environments in which the fluorophore could be found and 
determination of the location of the source (Truong et al. 2001).  
 
5.5.2 Bac7(1-35) biodistribution in mice 
The day before the treatment, healthy CBA mice were anesthetized by an intramuscular 
injection of a diluted mixture (1:5 in PBS) composed by 0.4 ml Zoletil 100 and 0.25 ml 
Rompun 2% (3 l/g body weight), and shaved in the regions of interest to avoid laser 
scattering caused by hair. The following day, mice were anesthetized using a gaseous 
anaesthesia chamber and the animals were then placed inside an eXplore Optix 
instrument in the presence of 1% isoflurane. Two mice were then injected 
intraperitoneally with 36.6 g/mouse of Bac7(1-35)-Alexa 680, corresponding to 6.9 
nmol ALEXA FLUOR 680. One mouse was monitored in the abdominal region and 
the other in the renal region for 24 hours. A blank image was acquired before treatment 
of each animal and this was subtracted to the images of the treated animal. The 
experiment was repeated twice. The small-animal time-domain eXplore Optix 
preclinical imager (GE Healthcare) was used in this study. In all imaging experiments, a 
670 nm pulsed laser diode with a repetition frequency of 80 MHz and a time resolution 
of 12 ps light pulse was used for excitation. The fluorescence emission at 700 nm was 
collected and detected through a fast photomultiplier tube and a highly sensitive time-
correlated single-photon counting system. Two-dimensional scanning regions of interest 
(ROI) were selected and the laser power, integration time and scan step were optimized 
according to the signal emitted. The data were recorded as temporal point-spread 
functions, and the images were reconstructed as fluorescence intensity and lifetime. 
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6. PEGYLATION STRATEGIES 
 
6.1 Pegylation of Bac7(1-35) via amide bond 
Metoxy-PEG20K-NH2 was used to pegylate the Carboxy terminal of Fmoc-Bac7(1-35). 
Fmoc-Bac7(1-35) (8.8 mg) dissolved in 500 l of DMF was added to 200 mg Metoxy-
PEG-NH2 dissolved in 1 ml of DCM (1:5 ratio of Bac7:PEG) in the presence of 0.38 
mg 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC), N-Hydroxybenzotriazole 
(HOBt), and triethylamine (TEA) added dropwise. The reaction was left to occur at pH 
8, under nitrogen stream at 50°C for 4 h and carried on overnight at room temperature. 
At the end of the incubation time, the mixture was precipitated by using an ether 
solution followed by heated ethanol. The mixture was filtered, dried and then separated 
by RP-HPLC using a strong cation exchange column (HITRAP SP, Waters Delta-Pak
TM
 
C4, 5 m, 2x150 mm). 
 
6.2 Pegylation of Bac7(1-35) via ester bond using a Glycine residue as linker 
Metoxy-PEG20K-OC(O)-Gly-NH2 was prepared as described (Ballico et al. 2005). 
Briefly, the metoxy-PEG20K-OH was dissolved in 1 ml of DCM with the addition of 
Boc-Glycine-OH (8 equimol) and 4-Dimethylaminopyridine (DMAP) (10 equimol). 
DIPEA was then added dropwise and the reaction was left to proceed overnight at room 
temperature and under stirring. The mPEG-Gly-Boc obtained was precipitated by using 
ethyl ether and the Boc-group was then removed by dissolving the compound in 10 ml 
of a TFA/DCM (1;1 v/v) solution. After 2 h of incubation, the mixture was precipitated 
with ethyl ether and dried under vacuum. The purity and the identity of the m-PEG20K-
OC(O)-Gly-NH2 obtained were then determined by H-NMR analysis (NMR 400 MHz).  
m-PEG20K-OC(O)-Gly-NH2 (120 mg) was then used to pegylate 5 mg of Fmoc-
Bac7(1-35) (1:5 ratio of Bac7 to PEG) at the C-terminus by following the same 
procedure described in section 6.1 of Materials and Methods. At the end of the 
incubation time, the mixture was precipitated by using ether followed by heated ethanol, 
filtered, dried and then separated by RP-HPLC using a strong cation exchange column 
(HITRAP SP, Waters Delta-Pak
TM
 C4, 5 m, 2x150 mm).  
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6.3 Pegylation of Bac7(1-35)-Cys via thioether ligation 
Metoxy-PEG20K-OC(O)CH2Br was prepared by dissolving 2 g mPEG20K-OH in 10 
ml of dry DCM and by adding 200 mg BrCH2COBr (10:1 ratio) dissolved in 2 ml 
DCM, under N2 at -20°C. DIPEA was then added dropwise. After 1 h of incubation at 
room temperature, the solution was directly passed through a SiO2 Column (10 x 10 
mm) and washed with 10 ml of DCM. Isopropyl alcohol (15 ml) was then added and the 
DCM was evaporated under vacuum at 30 °C. The recovered compound was 
precipitated with ethanol, cooled in ice bath for 30 min, filtered, washed with ethanol 
and dried under vacuum. The identity and the purity of the product were determined by 
RP-HPLC/ELSD (Evaporative Light Scattering detector) detection (Phenomenex 
Jupiter C4, 4.6 x 150 mm) and 
1
H-NMR analysis (NMR 400 MHz,), respectively.  
Pegylation was performed by adding BrCH2COOPEG-OMe to H-Bac7(1-35)-Cys(H)-
OH. Before use, the peptide (5 mg) was reduced to remove oxidized Cys-Cys dimers. 
To this aim, it was treated for 30 min with 5 l of a 62 mg/ml solution of tris(2-
carboxyethyl)phosphine-HCl (TCEP.HCl) in 145 l of phosphate buffer (0.3 M) at pH 
7.6, and mixing from time to time. BrCH2COOPEG-OMe (23 mg) was then added to 
the solution. After 3 h of incubation at room temperature, the pH was adjusted to 3 
with 50% TFA to quench the reaction, and the product was then separated by RP-HPLC 
by using a Jupiter C4 column Jupiter, Phenomenex.  
 
6.4  Tricine SDS-PAGE to detect pegylation efficiency 
Tricine SDS-PAGE was performed to verify the efficiency of the pegylation reaction 
and to identify the fractions containing the pegylated peptide after the purification 
procedure. 
According to the protocol described by Shagger (2006), samples, mixed with SDS-
containing reducing sample buffer, were loaded onto the 4% stacking gel by applying a 
potential difference of 50 V and then resolved in the 16% acrylamide running gel at 100 
V. To visualize the peptide and the band corresponding to PEG, the gel was respectively 
stained with Coomassie Blue and with BaCl2 and Iodine solution (Morpurgo and 
Veronese, 2004). Both staining procedures were done on the same gel using the 
Coomassie staining first.  
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6.5  Determination of the concentration of the pegylated peptide  
The concentration of the pegylated peptide was determined by three methods: 
I. by weighing the pegylated peptide after lyophilization  
II. by using the Waddell method  
III. by analytical RP-HPLC using an internal standard. 
 
6.6  Detection of Bac7(1-35)-Cys-CH2COOH release from mPEG-OH in  
human fluids 
To investigate the kinetic of release of the peptide in blood components by proteolytic 
cleavage of the ester bond between the mPEG-OH and the CH2COOH group, western 
blot analyses of the Bac7(1-35)-Cys-CH2CO(O)-PEGm incubated at different times in 
25% of human serum or plasma were performed. Bac7(1-35)-Cys-CH2CO(O)-PEGm 
(172 g) was incubated at 37°C in 150 l of PBS containing 25% (v/v) human serum or 
plasma. At different times, aliquots were withdrawn, diluted 1:5 in sample buffer, 
treated and then analysed as described in section 4.2 (Western blot analyses) of the 
current chapter. 
 
6.7 Antibacterial activity of the pegylated peptides 
To investigate the antibacterial activity of the Bac7(1-35) peptide pegylated via amide 
bond and thioether ligation, the broth microdilution susceptibility assay was perfomed 
in the presence of 25% of human serum or plasma as described in section 4.1. 
 
6.8 Biodistribution of the pegylated Bac7(1-35)-CAM-PEG  
BAC7(1-35)-Cys(Alexa Fluor® 680 C2-maleimide-)-CO-OPEG-OMe was prepared by 
native chemical ligation between Bac7(1-35)-COSPhNHAc and H-Cys(H)-COOPEG-
OMe, followed by thioether ligation with Alexa Fluor® 680 C2-maleimide. 
 
6.8.1 Synthesis of Bac7(1-35)-Cys-CO-OPEG-Ometoxy 
Bac7(1-35)-SPhNHAc was firstly prepared. In brief, Boc-Bac7(1-35)-OH (212.5 mg) 
and HS-Ph-NHAc, (2.25 mg) were dissolved in 1 ml of DCM/DMF (1:1, v/v), followed 
by addition of 31.2 mg of DIEA. The solution was cooled in an ice bath for 15 min and 
then 62 mg of PyBop were added. After mixing for 10 min at 4°C and for 35 min at 
room temperature, the DCM was evaporated under a stream of N2. To cooled in ice bath 
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and vigorously stirred reaction mixture of Boc-Bac7(1-35)-SPhNHAc were added 9 ml 
Ethanol/Petroleum ether (1:2, v/v). The oil formed was separated by centrifugation, 
washed with Ethanol/Petroleum ether (1:2, v/v) and dried under vacuum. Bac7(1-35)-
SPhNHAc was then purified by preparative RPHPLC (RCM C18 100 x 40 mm). 
H-Cys-CO-OPEG-Ometoxy was then prepared by dissolving 585 mg of Boc-Cys(Trt)-
OH in 1.4 ml of dry DMF and 0,1 ml of dry pyridine and by adding 2 g of 20 kD 
mPEG-OH dissolved in 8 ml of dry DCM and shaken overnight. The product was 
precipitated and washed with ethanol. After drying, it was redissolved in a mixture of 5 
ml DCM and 15 ml of isopropanol, precipitated in Ethanol and cooled for crystalization. 
The crystals formed were filtered, washed with Ethanol and dried in vacuo. The identity 
of the product was determined by RP-HPLC/ELSD detection (Phenomenex Jupiter C4, 
4.6 x 150 mm). Boc-Cys(Trt)-CO-OPEG-Ometoxy was then deprotected by dissolving 
it in 0,2 ml of DCM/(TFA/H2O/TIPS 90:5:5 v/v). After 1 h the solvent was evaporated 
under a stream of N2, the rest was mixed with Ethanol, precipitated and separated by 
centrifugation. 
To obtain Bac7(1-35)-Cys(H)-COOPEGOmetoxy, native chemical ligation of Bac7(1-
35)-SPhNHAc and H-Cys(H)-COOPEGOmetoxy occurred. H-Cys(H)-COOPEG-
Ometoxy (80 mg) was dissolved in 1 M phosphate buffer-EDTA pH 7.3 containing 0.05 
mg TCEP.HCl and the solution was flushed with N2; H-Bac7(1-35)-SPhNHAc (10 mg) 
was then added and the reaction was left to occur. After 28 h of incubation at room 
temperature, the reaction was quenched by adding cysteine (2.4 mg) and TCEP (60 g) 
and mixed for addition 2 h. Then the solution was diluted with 20 ml water, acidified to 
pH 3.5 with 10% H3PO4 and applied for purification by IE chromatography and RP-
HPLC/ELSD (Phenomenex Jupiter C4, 4.6 x 150 mm). 
 
6.8.2  Labelling of  the pegylated peptide 
Alexa Fluor 680 C2-maleimide was coupled to H-Bac7(1-35)-Cys(H)-COO-PEG-Om 
via thioether ligation in order to obtain H-Bac7(1-35)-Cys(AlexaFluor680 
C2maleimide)-COOPEG-Om. 
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Fig. 2. Structure of the pegylated Bac7(1-35) labelled with Alexa Fluor 680 C2. 
 
Briefly, Bac7(1-35)-Cys(H)-CO-OPEG-Om (25 mg) was dissolved in 0.5 M posphate 
buffer pH 7 (0.3 ml) and water/TCEP/EDTA (0.3 mg /0.1 ml water in total 0.4 ml) and 
mixed for 15 min. One mg of Alexa680 was then added and the mixture was stirred 
under N2 for 2 h, quenched with 10% H3PO4 to pH 4. The mixture was diluted with 
water (21 ml) and the product separated on semi-preparative RP-HPLC by using a C4 
column (Phenomenex 250 x 10 mm). 
The concentration of the labelled pegylated peptide was determined by at least three 
methods: 
I. by weighing the peptide used to prepare the solution; 
II. by using the Ellmann’s reagent method to detect free SH (Ellmann 1959);  
III. by considering the extinction coefficient ( 679) of Alexa Fluor 680. 
 
6.8.3 Bac7(1-35)CAM(Alexa680)PEG20k biodistribution 
Biodistribution analyses of Bac7(1-35)CAM(Alexa680)PEG20k in mice were 
performed as described in section 5.5.2 of the current chapter. In this case, three Balb-c 
male mice 5-week old were used. The background signal intensity, recorded with the 
baseline image for each animal before the injection of the probe, was subtracted from 
each post contrast image. Twentyfour hours after sample injection, the animals were 
sacrificed and ex vivo optical imaging of specific organs was performed. 
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7. EFFECTS OF Bac7(1-35) ON HUMAN MACROPHAGES 
 
7.1  Mammalian cells 
The human macrophage-like cell line U937 was maintained in RPMI 1640 medium 
supplemented with 2 mM L-glutamine, 100 U/ml of penicillin, 100 g/ml of 
streptomycin and 10% fetal bovine serum (FBS). For induction of differentiation, the 
cells (1x10
6
 per ml) were seeded in the same medium and treated with 50 ng/ml of 
PMA at 37 °C for 72 h in a 5% CO2atmosphere. After incubation, non-adherent cells 
were removed by aspiration and the adherent ones were washed with PBS. The cells 
were then incubated with trypsin solution [0.5% trypsin (w/v) in PBS containing 0.2 
mM EDTA] for 5 minutes at 37°C in 5% CO2, to detach them from the tissue culture 
flask. 
The human monocytes were isolated from a pool of buffy coats from different donors. 
The buffy coats were diluted 1:1 with PBS and added to an equal volume of Histopack. 
After centrifugation for 30 min at 400 x g without brake, the white band at the interface 
between the plasma and the Histopack fractions was soaked up, transferred into a 
Falcon sterile tube and washed twice with PBS. The cell pellet was then resuspended in 
fresh medium and transferred to a cell culture flask. After the monocytes were left to 
adhere for 1 h, the lymphocytes were washed away. The differentiation of the seeded 
monocytes was induced by addition of 50 ng/ml of S. typhimurium LPS followed by 
incubation at 37 °C for 5 days in 5% CO2. 
 
7.2  Citotoxicity assay 
The U937 cell line was grown and differentiated to macrophages as described above.  
The cells were seeded in 12-well tissue culture plates at a density of 4x10
5
 cells per well 
and incubated with or without peptide [10, 30, 50 and 150 M Bac7(1-35)] at 37 °C for 
3 h in 5% CO2. Two identical plates were prepared. At the end of the incubation time, 
the samples of the first plate were immediately analyzed to evaluate the cytotoxic effect 
of the peptide, while the analysis of the other plate was performed after replacement of 
the medium with fresh RPMI 1640, and extension of the incubation time up to a total of 
24 h.  
At the end of each incubation time (3 or 24 h), the cells were stained in the dark at 37 
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°C for 15 min with 50 nM of 3,3’-dihexylocarbocyanide iodide (DiOC6), a fluorescent 
probe used to measure the mitochondrial transmembrane potential in intact cells. A 
positive control for collapse of mitochondrial transmembrane potential was obtained by 
incubation of the cells with 50 M of the uncoupler carbonyl cyanide 3-
chlorophenylhydrazone (CCCP) for 15 min at 37 °C. 
To test their viability after treatment with DiOC6, the cells were washed twice with 2 ml 
of PBS, stained at room temperature and in the dark with 10 g/ml of propidium iodide 
(PI) for 10 min, and analyzed by flow cytometry, acquiring at least 10,000 events for 
each sample. 
The double staining with DiOC6 and PI allows distinguishing three subsets of cells: 
viable cells (DiOC6 positive and PI negative), apoptotic cells (DiOC6 negative and PI 
negative), and necrotic cells (DiOC6 negative and PI positive).  
 
7.3 Peptide uptake by differentiated U937 cells 
 
PMA-differentiated U937 monocytic-like cells (3 x 10
4
 cells per well) were incubated 
for 3 h with or without 1 M Bac7(1-35)-BODIPY. The cells were then washed with 
PBS, to remove the non-internalized peptide, and analysed by fluorescence 
spectroscopy. The analyses were also performed by using flow cytometry before and 
after addition of 1 mg/ml Trypan blue, an extracellular quencher that is not internalized 
in intact cells.  
The cells were also analysed by confocal laser microscopy (see section 3.6 of Materials 
and Methods). 
 
7.4 Phagocytosis assay 
 
The gentamicin-protection invasion assay was used to test phagocytosis (Su et al 2010). 
The S. enterica LT2 suspensions were seeded to each well of a flat-bottom well tissue 
culture plate to achieve the desired cells to bacteria ratio (multiplicity of infection, 
MOI). PMA-differentiated U937 monocytic-like cells in RPMI supplemented with 10% 
FBS were then added to the plate. After allowing phagocytosis to occur for 1 hour, 
gentamicin was added to each well at 18 g/ml and left at 37 °C in 5% CO2 for 1 hour. 
The added gentamicin kills extracellular bacteria without affecting the viability of 
intracellular bacteria and of macrophages.  
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7.4.1 Effects of Bac7(1-35) on Salmonella phagocytosis by use of GFP-
expressing bacteria 
 
Phagocytosis assays were performed as described above (section 7.4) by incubating 
PMA-differentiated U937 monocytic-like cells (1 x 10
5 
per well) and GFP-expressing S. 
typhimurium cells in a 24-well plate, at a MOI value of 50,. The experiments were 
performed in duplicate by pre-treating the cells with 50 M Bac7(1-35) at 37 °C for 1 h, 
or, vice versa, by pre-treating the bacteria with 0.5 M peptide. At the end of the 
incubation time, samples were collected, centrifuged at 400 x g for 5 min, and the cells 
resuspended in PBS to allow flow cytometric analysis. 
 
7.4.2  Phagocytosis assay to evaluate the protective effect of Bac7(1-35) against 
intracellular Salmonella survival and replication 
 
Phagocytosis assays were performed as described above (section 3.4) by using PMA-
differentiated U937 monocytic-like cells (4 x 10
5 
per well) or macrophages derived 
from human monocytes (MDM) after LPS treatment (50 ng/ml) and S. typhimurium at a 
MOI of 10. 
At the end of the phagocytosis assay, the medium was removed and replaced with fresh 
RPMI containing 10% FBS with or without peptide added at 50 or 150 M. For each 
sample, three identical wells were prepared. The cells of the first well were collected 
and plated after phagocytosis and immediately before peptide’s addition. Those of the 
second well were treated with the peptide for 3 h and then plated. The cells of the third 
well were treated with the peptide for 3 h and then washed with abundant PBS to 
remove the peptide, supplemented of fresh medium and allowed to incubate for 
additional 21 hours at 37°C in 5% CO2. A control without peptide addition was 
prepared for each sample (first well).  
At the end of the incubation time, PBS was added to each well and the cells were 
collected, centrifuged at 400 x g for 5 min, and counted. To recover phagocytosed 
bacteria, the cells were then lysed by treatment with 1 ml of 0,1% Triton X-100 in PBS 
for 30 min at room temperature. The bacteria were then diluted, plated on MH agar 
plates, incubated overnight at 37 °C to allow colony counts. Significance of percentage 
differences among the number of bacteria within the peptide-treated and untreated cells 
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at 3 h and 24 h was calculated by using the t-test. Values of p <0.05 were considered 
statistically significant. 
 
7.4.2.1.1 Flow cytometer and data analysis 
Flow cytometry is a powerful technique that is used in a range of applications for the 
analysis of multiple parameters of individual cells within a heterogeneous population. 
The flow cytometer performs this analysis by passing thousands of cells per second 
through a laser beam and capturing the light that emerges from each cell as it passes 
through. The data acquired can be analyzed statistically by dedicated software that 
reports cellular parameters such as size, complexity, phenotype and viability. As shown 
in Fig. 3, the flow cytometer is generally composed of: 
- a fluidic system which presents cells to the interrogation point and takes away the 
waste; 
- the lasers, which are the light source for scatter and fluorescence; 
- the optics, which gather and direct the light 
- the detectors (photomultipliers), which receive the light 
- the electronics and computer system that convert the signals from the detectors into 
digital data. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. Schematic representation of a flow cytometer. 
 
A cell that passes through the laser beam scatters light at all angles. Forward scatter, or 
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low-angle light scatter, is the amount of light that is scattered in the forward direction 
and is dependent on the cell size. Side scatter is the large-angle light scattering 
dependent on the granularity and structural complexity inside the cell. The scatter plot 
created using the forward and side scatter data, gives a distribution of the cells in the 
analyzed population based on their size, granularity and structural complexity (Fig. 4). 
 
 
 
 
Fig. 4. Scatter plot: the plot represents the distribution of a cells population and is 
obtained by plotting the forward (x-axis) and side (y-axis) scatter values of each 
individual cell. 
 
One of the most common ways to study cell characteristics using flow cytometry 
involves the use of fluorescent molecules. When fluorescent cells pass through the laser 
beam and the laser light of the right wavelength strikes the fluorophore, a fluorescent 
signal is emitted and directed to the appropriate detector. This translates the signal in a 
voltage pulse proportional to the amount of fluorescence emitted by each cell. The 
fluorescence intensities of all the cells analysed are described by a normal distribution 
and the Mean Fluorescence Intensity (MFI) of the cell population can be calculated 
(Fig. 5). 
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Fig. 5. Fluorescence Histogram: the histogram, on the right, represents the normal 
distribution of the fluorescence intensities of all the cells counted (events), which were 
selected among the cell population analysed (R3 in the scatter plot on the right).  
 
7.5 Confocal Laser analysis  
Confocal Laser Microscopy analyses were performed to evaluate the peptide uptake into 
the cells and its biodistribution after phagocytosis. For the former type of evaluation, the 
U937 cells (1 x 10
6
) were seeded on coverslips in complete medium supplemented with 
50 ng/ml PMA to induce differentiation into macrophages. After 3 days of incubation at 
37°C and in 5% CO2, the culture medium was removed. The cells were then washed 
with abundant PBS and stained at 37 °C and 5% CO2 with FAST DiI (0.5 mM) diluted 
in 0.5 ml of fresh complete medium. After 20 min of staining, the cells were washed 
with PBS before adding medium supplemented with 10% FBS and Bac7(1-35)-
Alexa680 (1 M) for 1 h and 3 h. The peptide solution was then aspirated; the cells 
were washed several times with PBS, and then fixed with 2% paraformaldehyde in PBS 
for 20 min at room temperature. After washing three times, the fixed cells were treated 
with 0.1% glycine and 0.02% NaN3 in PBS for 5 min. After permeabilization with 
0.01% Triton X-100 for 5 min, the cells were rinsed three times with PBS and once with 
deionised water. The slides were mounted with Mowiol and conserved in the dark at -
20°C until examination by fluorescence microscopy.  
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To analyse the uptake and biodistribution of the peptide after phagocytosis, cells were 
stained with FAST DiI solution as described above. After washing, the cells were 
resuspended in RPMI medium supplemented with 10% FBS, and the GFP-expressing 
salmonellae, prepared as described in section 2.1, were added at a MOI 50. 
Phagocytosis was left to occur for 2 h. Coverslips were then washed three times with 
PBS and treated with 1 M Bac7(1-35)-Alexa for 3 h. The peptide solution was then 
aspirated and the cells were washed several times with PBS, fixed, treated as described 
above, and stored in the dark at -20°C. All the samples were examined with a Nikon 
C1-SI confocal microscope with an oil immersion objective lens. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Results 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 59 
9 
1. THERAPEUTIC POTENTIAL of Bac7(1-35): in vitro and in vivo ACTIVITY 
 
1.1 Antibacterial activity of Bac7(1-35) in the presence of serum and plasma 
Before testing Bac7(1-35) in vivo, its antibacterial activity was assayed in vitro in the 
presence of serum and plasma. Killing kinetics assays were firstly performed in the 
presence of 66% (v/v) murine serum or plasma towards S. enterica. The results showed 
that murine serum and plasma exert a time-dependent inhibitory effect on the 
bactericidal activity of Bac7(1-35), reducing significantly its efficacy (Fig. 1.1).  
   
 
                   
        
 
Fig. 1.1. Antimicrobial activity of Bac7(1-35) in the presence of murine serum or plasma 
Kinetics of the bactericidal activity of 10 M Bac7(1-35) against S. enterica ATCC 14028 in 
the absence (blue line) or in the presence of 66% murine serum (pink line) or 66% murine 
plasma (green line). Bacterial growth without peptide in the absence () or presence of 66% 
serum () or plasma () is shown by black lines. Results represent the mean  SD of three 
independent determinations performed in triplicate.  
 
In particular, after 1h-incubation with serum or with plasma, 10 M Bac7(1-35) reduced 
the number of CFU by 0.5-1 log vs 2.5 log detected in the absence of the blood 
components. After 4h-incubation, Bac7(1-35) was able to reduce the number of CFU 
both in serum and plasma by 2 log compared to the control (i.e., bacteria without 
peptide in the absence or presence of 66% biological fluids) but its efficacy decreased if 
we compare it with that shown by the peptide in culture medium. At longer incubation 
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times, the activity of the peptide was further inhibited especially by murine serum. In 
fact, after 8 h incubation, the number of CFUs in the presence of peptide and serum, 
increased of 2 log with respect to the peptide in MH. Killing kinetics assays were also 
performed in the presence of BSA at physiological concentrations (40 mg/ml) so as to 
investigate its possible effect on Bac7(1-35) antibacterial activity. Results showed that 
this serum protein does not alter the activity of the peptide (data not shown). 
In order to investigate whether these inhibitory effects are also observed in the presence 
of human blood components, microdilution susceptibility assays were performed to 
determine the minimum inhibitory concentration (MIC) of Bac7(1-35) in the presence 
of 25% human serum and plasma. In parallel, the MIC values were also tested in 25% 
murine serum or plasma, to compare the effect of fluids from the two species. 
 
Table 1.1 Antimicrobial activity of Bac7(1-35) in human or murine biological fluids. 
 
 
 
 
 
 
 
MIC values of Bac7(1-35) towards S. enterica (10
5
 CFU/ml) in the presence of 25%   murine 
serum or plasma, human serum or plasma diluted in MH broth or in 100% MH. Data shown are 
representative of three independent experiments with comparable results. 
 
As expected from the kinetics results previously reported, the MIC value of Bac7(1-35) 
in murine blood components drastically increased. In serum and in plasma the peptide 
was active respectively at concentrations 128- and 64-fold higher than in culture broth 
alone (Table 1.1). Interestingly, when the same assay were repeated with human serum 
or plasma, the results were quite different. Bac7(1-35) in human serum was active at the 
same concentration showed in Mueller-Hinton broth: no inhibitory effects were detected 
and the peptide inhibited the bacterial growth at 0.5 M. To evaluate the involvement of 
the complement in enhancing the antibacterial effect of the peptide, the assays were also 
repeated using heat-inactivated serum (30 min at 56 °C). Results showed that there was 
no difference in the MIC values (data not shown), indicating that the effect was not 
dependent on complement activation. 
In human plasma, Bac7(1-35) seemed to potentiate its activity: the MIC value increased 
  MIC (µM)  
 Human  Murine Mueller-Hinton 
 Plasma  Serum  Plasma Serum  
S. enterica 
ATCC 14028 
0.06-0.12 0.5 32 64 0,5 
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4-8 folds with respect to the MIC value in MH or in the presence of human serum. This 
effect was also observed with other peptides, such as BMAP-27, and the Bac7 
fragments 1-15 and 1-16, that were tested in the presence of human plasma (Table 1.2). 
Since we observed that in human plasma the kinetics of bacterial growth is slowed 
down (data not shown), it can be hypothesized that there is a synergistic effect between 
peptide and serum that leads to an improve activity. 
 
Table 1.2. Comparison of the antimicrobial activity of different peptides in human 
plasma or in culture medium
 
 
 
 
 
 
 
 
 
 
MIC values of BMAP-27, Bac7(1-16) and Bac7(1-15) towards S. enterica (10
5
 CFU/ml) in the presence 
of 25% human plasma diluted in Mueller Hinton broth or in 100% Mueller Hinton. Data shown are 
representative of three indipendent experiments with comparable results. 
 
1.2 Stability of Bac7(1-35) in serum and plasma 
 
One of the main causes of short in vivo half-life of peptides and proteins is their 
enzymatic degradation (Werle and Bernkop-Schnurch 2006). Following this 
consideration, the degradation of Bac7(1-35) by blood components was studied to 
verify if the reduced activity of the peptide in mouse fluids was due to this reason. 
Western blot analyses were performed after incubation the peptide in human or murine 
serum or plasma up to 72 h. In murine serum, immunodetection indicated a slow and 
progressive reduction of the band corresponding to intact Bac7(1-35), which 
disappeared completely after 24 h-incubation (Fig. 1.2A). In plasma, where proteases of 
the coagulation cascade are not activated, the degradation level of Bac7(1-35) appeared 
slightly lower than in serum. In contrast, in human fluids, the effects of proteolytic 
 MIC (µM) S. enterica ATCC 1402  
 Human                    Mueller 
Plasma                     Hinton  
BMAP-27 0,5                1 
    Bac7(1-16)         0,5 1 
   Bac7(1 -15)         16 32 
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degradation were much slower. In fact, a visible decrease in the amount of intact 
peptide could only be detected after 48 h of incubation and a significant amount of it 
was still present after 72 h (Fig. 1.2B). 
 
A) 
 
 
 
 
 
 
 B)  
                        
 
 
 
                  
 
 
 
 
Fig. 1.2. Western blot analyses of Bac7(1-35) degradation by biological fluids. The peptide 
was incubated for different times at 37 °C in 25% (A) murine and (B) human serum and plasma.  
 
A quantitative evaluation of Bac7(1-35) degradation was carried out by using LC-MS 
analysis. Results were in agreement with those obtained by Western Blot analysis.  The 
amount of intact peptide decreased of 40% after 4 h of incubation in murine serum and 
disappeared almost completely after 8 h. In human serum, the reduction was much 
lower as already indicated by Western blot analysis. (Fig. 1.3).  
 
      
Bac7     0h         1h       4h          8h     24h  serum
Bac7     0h       1h       4h        8h       24h   plasma
Plasma
Serum
Serum
Plasma
Bac7        0h        8h        24h         48h       72h   serum
Bac7        0h        8h        24h         48h       72h   plasma
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Fig. 1.3. Bac7(1-35) degradation by blood fluids analyzed by LC-MS. The percentages of 
intact Bac7(1-35) at the different incubation times in human serum (blue line) and murine serum 
(green line) or plasma (pink line) were calculated with respect to an untreated control. Data are 
from an experiment representative of three independent experiments with comparable results.  
 
The lack of detection of fragments of Bac7(1-35) by LC-MS has to be pointed out and 
likely depends on generation of small, undetectable hydrophilic fragments. This 
fragmentation likely depends on the trypsin-like serine proteases of blood, which could 
cleave the peptide in correspondence of the many Arg residues present in its sequence.  
 
1.3  In vivo toxicity of Bac7(1-35) 
 
The determination of acute toxicity represents the first step in a preliminary evaluation 
of the therapeutic potential of a drug candidate. To this aim, Bac7(1-35) was injected 
via i.p. at increasing doses in mice of two different strains, Balb/c and CBA/CA, and 
mice survival was monitored up to 14 days. According to standard procedures, we also 
monitored the weight and the aspect of the hair of treated mice as sign of toxicity or 
pain. Up to the dose of 75 mg/kg mice did not show any apparent sign of suffering, the 
weight remained stable within the 14 days and their hairs that did not show any change. 
At the highest dose tested, 150 mg/kg, all mice died within 3 days. From these data and 
using the Wilcoxon and Mann-Whithey test, it could be calculated that the LD50 value 
for Bac7(1-35) is 105 mg/kg. This result confirms that Bac7(1-35) is much less toxic 
than other cathelicidin-derived peptides as BMAP-27 and BMAP-28 [LD50 respectively 
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10 and 15 mg/kg (Benincasa et al. 2004)].  
 
1.4  In vivo Bac7(1-35) activity in a mouse model of typhoid fever 
 
The capacity of Bac7(1-35) to protect mice from a bacterial challenge was tested in a 
mouse model of Salmonella infection. Animals infected with this pathogen develop a 
systemic disease characterized by rapid bacterial multiplication in the liver and spleen 
that resembles typhoid fever caused by Salmonella serovar Typhi in humans (Santos et 
al. 2001). CBA/CA mice were chosen for this assay because Balb/c mice were 
extremely susceptible to Salmonella infection, due to an intrinsic defect in cell-mediated 
immunity (Hormaeche et al. 1981, Takahashi et al.  1990). 
Previous studies performed to determine the lethal dose of S. enterica ATCC 14028 in 
the CBA/CA strain, indicated that injection via i.p. of a bacterial suspension of 1x10
2 
CFU/mouse was sufficient to cause death of untreated mice at around 10 days. 
Gentamicin, which was chosen as control to validate the experimental model, gave 
100% of protection against infection at the dose of 10 mg/kg.  
Bac7(1-35) at a dose of 30 mg/kg was injected via i.p. immediately after infection. This 
dose was chosen in light of preliminary in vivo experiments in which the use of 15 
mg/Kg Bac7(1-35) did not protect the infected animals (only a minor improvement in 
survival was observed with respect to untreated controls, data not shown). The number 
of survivors was monitored for 60 days and compared to that of control mice that only 
received the lethal bacterial challenge. The survival curves of untreated and peptide-
treated mice are significantly different (p <0.05); the mean survival time of control mice 
was 10 days, while the treatment of infected mice with Bac7(1-35) increased the mean 
survival time to 24.5 days (Fig. 1.4A). A group of peptide-treated mice was also 
analysed for bacterial load at 3 days post-infection and, at this time, mice did not show 
any visible sign of disease. Viable bacterial cells were counted in murine liver and 
spleen of infected mice. These are in fact the main organs that are infected by 
Salmonella once in the systemic circle (Gulig 1996; Falcow et al. 1996). Results 
showed a great reduction in the number of viable bacterial cells in liver and spleen of 
treated mice compared to those detected in untreated mice, despite the high variability 
in each group (Fig. 1.4 B). 
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A)                                                                          B)  
 
Fig. 1.4. In vivo activity of Bac7(1-35) in a salmonellosis animal model. (A) Survival curves 
of mice infected with S. enterica ATCC 14028 and treated with Bac7(1-35) (dotted line). 
Control mice were given 0.2 ml of PBS (continuous line). Mice were monitored over a period of 
60-days after infection. *p<0.05 treated vs untreated mice. (B) Viable bacterial counts in liver 
and spleen homogenates. Three days after infection, untreated (squares) and peptide-treated 
(triangles) mice were killed, and liver (full symbols) and spleen (empty symbols) were collected 
and homogenized in order to allow bacterial colony counts Results are expressed as number of 
CFU/g organ, horizontal bars represent the mean value for each group.  
 
In 3 out of 10 of the animals, bacteria were undetectable in both the spleen and liver. 
This result is in keeping with the percentage of mice completely cured, as extrapolated 
by the survival curve (Fig. 1.4 A). Given that the model of infection tested is quite 
aggressive (i.p. injection of as few as 100 salmonellae is lethal for mice), the increased 
survival times and the eradication of the infection in 35% of the peptide-treated animals 
is a promising result. 
 
1.5  In vivo Bac7(1-35) biodistribution 
 
To better understand the behaviour of Bac7(1-35) in vivo and with the aim to modify it 
so as to improve its in vivo performance, we investigated the biodistribution and rate of 
clearance of the peptide in mice. To this aim, time-domain optical imaging analyses 
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were performed by using a derivative of Bac7(1-35) that was fluorescently labelled with 
the dye Alexa680, a modification that did not alter its antimicrobial efficacy. Time 
killing assays performed by incubating S. enterica with Bac7(1-35)-Alexa680 up to 8 h, 
revealed that the reduction of bacterial CFU differs of only half a log from that obtained 
with unlabeled Bac7(1-35)(data not shown). The peptide was thus injected via i.p. in 
mice at the dose used for in vivo studies, and its biodistribution was monitored up to 24 
h by acquiring the fluorescence intensity signal (lifetime) of the dye linked to the 
peptide as described in the Materials and Methods 5.5.1 section. To be certain that the 
fluorescence signal was derived from the conjugated peptide and not from the free dye, 
lifetimes of the two forms of dye were compared and resulted different. The 
fluorescence signal of the Bac7(1-35)-Alexa680 was detected in the kidney 1 h after i.p 
injection and in the bladder after 3 h. During the following hours, the fluorescence 
decreased and completely disappeared at 24 h (Fig. 1.5A). Ex vivo analysis performed 
on liver, kidney and spleen at 5 and 24 h confirmed these data: at 5 h the peptide was 
still present in the kidney but not in liver and spleen (data not shown); at 24 h post-
injection the fluorescent signal was not detectable in any of the organs collected (Fig. 
1.5B). These results indicate that Bac7(1-35) does not accumulate in any particular 
organ except those involved in the elimination processes and that in mice the peptide is 
characterized by a fast renal clearance after i.p. injection. In addition, ex vivo analyses 
allowed monitoring of the morphological aspect of the organs and no visible alteration 
due to the presence of the peptide was detected, suggesting that the peptide did not 
cause any macroscopic side effect. 
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Fig. 1.5 Biodistribution of Bac7(1-35)-Alexa680 in healthy mice after i.p. injection. (A) The 
animals were placed in prone position (upper panel) and supine position (lower panel); fluorescence 
emission in the regions of interest encompassing respectively the kidneys, the thorax and abdomen, 
were acquired at indicated times post-injection and normalized with respect to the prescan acquired 
before peptide injection. (B) Ex vivo images of organs at 5 h after i.p. injection of the labelled peptide. 
At 5 h post injection, the signal of Bac7(1-35)-Alexa was detected only in the kidney (not shown).  At 
24 h the signal of Bac7(1-35)-Alexa was not present. Images of the organs were acquired immediately 
after sacrifice: laser power and integration time were optimized while keeping constant scan step to 
compare fluorescence intensities after normalization. The images are representative of two 
independent experiments with comparable results. 
 
5 h post-injection
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 2. PEGYLATION STRATEGIES TO IMPROVE Bac7(1-35) 
BIODISTRIBUTION  
Due to its small size, Bac7(1-35) is easily cleared by kidneys, as also indicated by the in 
vivo imaging experiments. To overcome this problem and increase the pharmacokinetic 
profile of the peptide, it was decided to modify it by conjugation with PEG. Molecules 
are generally conjugated to PEG via amino-groups (Veronese et al. 2005). However, the 
internalization of Bac7(1-35) in the bacterial cytosol and its activity are strictly 
dependent on the presence of a cationic and free N-terminus (Benincasa et al. 2004). 
For this reason, conjugation of PEG was pursued to the C-terminus of the peptide. 
Different strategies were used in order to find the best one in terms of efficiency of 
reaction and biological activity of the pegylated peptide.  
2.1.  Bac7(1-35) pegylation via  amide bond 
In a first attempt, the pegylation of Bac7(1-35) was performed via formation of a stable 
amide bond involving the C-terminal carboxylic group of the peptide and an amino-
PEG (NH2-PEG20k-metoxy) with a MW of  20000 (Fig. 2.1). 
 
 
 
Fig. 2.1. Reaction of the C-terminal carboxylic group of Bac7(1-35) with an amino-
PEG (NH2-PEG20k-metoxy). 
 
 
At the end of the reaction, the pegylated peptide Bac7(1-35)PEG20k was purified using 
cation-exchange chromatography and RP-HPLC, and its purity was checked by SDS-
PAGE analysis (Fig. 2.2).  
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Fig. 2.2. SDS-PAGE analysis of  Bac7(1-35)-PEG20k.  
Tricine SDS-PAGE of the pegylated peptide before and after purification. Two different 
methods of staining were used specifically allowing the detection of the peptide and of 
PEG. The gel on the left is stained with Coomassie Blue to detect the band 
corresponding to the peptide and the gel on the right is stained with barium 
chloride/iodine solution to visualize the band corresponding to PEG. For each sample, 3 
g were loaded. The apparent mass of the bands corresponding to PEG is higher than 
expected (40k vs 20k) due to the high capacity of water to bind the polymer.  
 
As shown, this reaction allowed to obtain the pegylated form of Bac7(1-35) in good 
yield (  30%) and pure to homogeneity after appropriate chromatographic steps. The 
double staining with Coomassie and barium chloride/iodine solutions allowed detection 
of both PEG and peptide. The purified compound showed a distinct profile with respect 
to samples containing unpurified Bac7(1-35)PEG20k or the commercial PEG alone 
(Fig. 2.2). Unfortunately, Bac7(1-35) conjugated to amino-PEG showed a great loss in 
antibacterial activity. In fact, the MIC value against S. enterica increased from 0.5 µM 
for the free peptide to 32 M for the conjugate (Table 2.1).  
As for the unpegylated form, the activity of Bac7(1-35)-PEG20k decreased further in 
the presence of murine blood components and remained unchanged in the presence of 
human serum or plasma (Table 2.1). 
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Table 2.1. Antimicrobial activity of Bac7(1-35) and Bac7(-35)PEG20k in human and 
murine biological fluids 
 
 
 
 
 
 
 
MIC values of Bac7(1-35) and Bac7(1-35)-PEG20K towards S. enterica (10
5
 CFU/ml) in the 
presence of 25% of murine serum and plasma, human serum and  plasma diluted in Mueller 
Hinton broth, or in 100% Mueller Hinton. Data shown are representative of three independent 
experiments with comparable results. 
 
2.2  Bac7(1-35) pegylation via ester bond and thioether bond 
 
To overcome the lack of Bac7(1-35) activity when pegylated via a stable bond, as the 
amide bond above described, we used a different conjugation strategy based on the 
presence of a cleavable ester bond that could be the substrate of blood esterases, to 
allow a slow peptide release.  
To this aim, a glycine linker was first attached to 20k PEG via reaction of its carboxy 
group with the alcohol function of the polymer (OH-PEG20k-metoxy), to give a 
cleavable ester bond (Fig. 2.3). The C-terminus of Bac7(1-35) was then conjugated to 
the Gly amino group by forming an amide bond. The glycine residue was used to 
increase the efficiency of the conjugation between the peptide and PEG, which would 
otherwise be very low if the ester bond would be formed between the C-terminus of the 
peptide and the OH of a high molecular weight PEG molecule. When the ester bond of 
the obtained conjugate is cleaved, the Bac7(1-35)-Gly36 form of the peptide is released 
(Fig. 2.3 B). 
 MIC (µM) S. enterica ATCC 14028 
 
Human  Murine 
Mueller-
Hinton 
 Plasma  Serum  Plasma Serum  
 
Bac7(1-35) 0.06 –0.12 0.5 32 64 0.5 
Bac7(1-35)-PEG20K 32 32 64 128 32 
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A) 
B) 
 
 
 
 
Fig. 2.3. A) Scheme of the synthesis of the conjugate between Bac7(1-35) and OH-
PEG20k-metoxy via a glycine residue whose amino group forms an amide bond with 
the alcohol function of PEG. B) The arrow indicates the cleavable bond that can be 
hydrolyzed by esterases. 
 
As for the peptide pegylated via an amide bond, Bac7(1-35)-Gly-PEG20k was purified 
and analyzed by SDS-PAGE (Fig. 2.5 A). Despite a purified product has been detected, 
unfortunately the yield of the reaction was very low (  1%), leading to an insufficient 
amount of conjugate to test its biological activity. 
To increase the yield of the reaction, a quite different coupling strategy was adopted, 
based on a cleavable thioether bond, which makes use of Bac7(1-35) with a Cys 
residue added at its C-terminus and of the PEG derivative bromoacetyl-PEG-MeO. 
This procedure, known as thioether ligation or native chemical ligation, is a 
chemoselective approach that allows obtaining a very high yields of reaction (Brunel et 
al. 2005). Also in this case, a cleavable bond is obtained between the peptide and the 
PEG molecule in order to ensure a slow release of Bac7(1-35) in the systemic circle. In 
fact, the thioether bond formed between the acetyl group and the PEG molecule can be 
cleaved by blood esterases (Fig. 2.4 B). 
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A) 
 
 
 
 
 
 
 
 
B) 
 
Fig. 2.4. A) Scheme of the synthesis of the conjugate between Bac7(1-35) and acetyl-
PEG20k-metoxy via a cysteine residue by using the thioether ligation strategy. B) The 
arrow indicates the cleavable bond that can be hydrolyzed by esterases. 
 
The pegylated Bac7(1-35) compound was purified following the same procedures used 
previously and the purity of Bac7(1-35)-CAM-PEG20k was checked by SDS-PAGE 
(Fig. 2.5 B). 
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B) 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.5. Evaluation of the purity of the conjugates Bac7(1-35)-Gly-PEG20k (A) and 
Bac7(1-35)-CAM-PEG20k (B). Tricine SDS PAGE of the pegylated peptide before and 
after purification. The gel on the left is stained with Comassie Blue to detect the band 
corresponding to the peptide; the gel on the right is stained with Iodine solution to detect 
the band corresponding to PEG. For each sample, 3 g of peptide were loaded. 
 
 
This strategy allowed to obtain a pegylated Bac7(1-35) with a high yield of reaction 
Unpurified  
Bac7(1-35)-Gly-PEG20k 
3.    Purified  Bac7(1-35)-Gly-PEG20k 
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(  70%). As can be inferred from Fig. 2.5, the presence of non-reacted free peptide 
in the unpurified sample suggested that the reaction conditions were not yet fully 
optimized. Published data underline the importance of pH in the thioether ligation 
reaction (Tsutsumi et al. 2000). Taking into account this aspect, in a recent 
preparation a yield of  99% of the desired product was obtained.  
MIC assays, both in culture medium alone and in the presence of human and murine 
serum or plasma, were then performed to evaluate the antimicrobial activity of 
purified Bac7(1-35)-CAM-PEG20k. The results showed that the compound 
maintained a good antibacterial activity, although its potency was lower than that of 
unconjugated Bac7(1-35) (Table 2.2). 
 
Table 2.2. Antimicrobial activity of Bac7-PEG complexes against S. enterica in 
the presence or absence of human and murine biological fluids.  
 MIC (µM) S.enterica ATCC 14028   
 
Human  Murine 
Mueller-
Hinton 
 Plasma  Serum  Plasma Serum   
BAC7(1-35) 0.06-0.12 0.5 32 64 0.5 
 
Bac7(1-35)-CAM-PEG20k 2 8 32 64 8 
 
BAC7(1-35)-CAM 0.25 1 64 64 1 
 
BAC7(1-35)-CAM-PEG20k 48 h* 0.25 1 nd nd 1 
 
MIC values of Bac7(1-35), Bac7(1-35)-CAM and Bac7(1-35)-CAM-PEG20k towards S. 
enterica (10
5
 CFU/ml) were determined in the presence of 25% murine serum and plasma, 
human serum and plasma, diluted in Mueller Hinton broth, or in 100% Mueller Hinton. * 
incubated for 48 h in serum or plasma before the MIC assay. Data shown are representative 
of three indipendent experiments with comparable results. Nd: not determined. 
 
 
To further investigate on the efficacy of Bac7(1-35)-CAM-PEG20k, the MIC values 
against S. enterica in MH broth alone and in the presence of blood components were 
determined with the released form Bac7(1-35)-CAM from PEG molecule obtained 
after blood proteases activity (Fig.2.4 B). It showed an activity comparable to that of 
the unmodified Bac7(1-35) (table 2.2). The following step was to test the kinetics of 
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release of Bac7(1-35)-CAM from the complex with PEG: the conjugate was 
incubated with human serum or plasma up to 72 h and the product analyzed by 
Western blot (Fig. 2.6).  
 
 
 
 
 
 
 
 
 
Fig. 2.6. Evaluation of Bac7(1-35)-CAM release from PEG conjugates in the presence 
of human biological fluids. Western blot analyses of Bac7(1-35)-CAM-PEG20k in human 
serum (right panel) and human plasma (left panel). Bac7(1-35)-CAM-PEG20K was 
incubated in 25% human serum or plasma up to 72 h at 37 °C. Samples were then loaded on 
the  gel to allow peptide detection with a specific anti-peptide antibody. 
 
In human serum the release of Bac7(1-35)-CAM was already detectable after 8 h- 
incubation and was almost complete at 72 h. The band corresponding to the released 
peptide increased along time in spite of the peptide degradation process that is 
detectable in human serum from 48 h of incubation (see section 1.2 of the results).  
These results indicate that the kinetics of Bac7(1-35)-CAM release in human serum 
is slow as in human plasma and proteolytic degradation seemed to be negligible 
(Fig. 2.6). 
In order to verify whether the released product had an antimicrobial potency 
comparable to that of synthetic Bac7(1-35)-CAM, microdilution susceptibility 
assays were repeated with Bac7(1-35)-CAM-PEG20K after 48 h incubation in 25% 
human serum or plasma. The MIC value under these conditions improved 8-fold 
with respect to that of the non-preincubated, pegylated peptide, reaching the same 
potency exerted by Bac7(1-35)-CAM. This indicates that the peptide was completely 
released during the incubation time.  
CTRL     0h   4h       8h     24h       48 h    72h             CTRL     0h   4h       8h     24h       48 h    72h           
Bac7(1-35)-CAM-
PEG20k
1-35)CAM  
CTRL        0h   4h    8h    24h    48h    72h  CTRL    0h   4h     8h        24h    48h    72h      
Bac7(1-35)
PEG20k
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Overall, these results indicate that an active peptide can be released from Bac7(1-
35)-CAM-PEG20K by exposure of the conjugate to blood components for 48-72 h, a 
period of time in which the degradation of the peptide is negligible. 
 
2.3  In vivo Bac7(1-35)-CAM-PEG20K biodistribution 
To better understand the advantages of Bac7(1-35) pegylation via thioester ligation, 
in vivo biodistribution analysis were performed. To this purpose a derivative of 
Bac7(1-35)-CAM-PEG20k, fluorescently labelled with the dye Alexa680 has been 
recently synthesized. Two chemical strategies were followed to maintain the same 
conformation of the Bac7(1-35)-CAM-PEG20k molecule: the PEG molecule was 
linked to Bac7(1-35) via native chemical ligation while the Alexa Fluor680 with a 
maleimide group was linked to the thiol group of the cysteine residue present 
between Bac7(1-35) and CH2COO-PEG-OMe (Fig. 2.7). 
 
 
Fig. 2.7. Scheme of the synthesis of the conjugate between Bac7(1-35) and acetyl-
PEG20k-metoxy via a cysteine residue by using the native chemical ligation strategy 
followed by thioether ligation strategy. The obtained compound was then labelled 
with maleimide-Alexa FLUOR680
©
. 
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Biodistribution analyses in healthy mice were performed as previously described for 
Bac7(1-35)-Cys36Alexa680, by monitoring the availability of the labelled, pegylated 
peptide up to 24 h after its intraperitoneal administration and performing ex vivo 
analysis at 24 h. Preliminary results showed that the pegylated peptide had a much 
wider distribution than the unpegylated one and was detected in different organs 
(Fig. 2.8 A and B). Furthermore, it was still present at 24 h post-injection (Fig. 2.8 
B), showing a slower renal clearance compared to the unmodified peptide (Fig. 1.5). 
Ex vivo analysis showed a significant concentration of the pegylated Bac7(1-35)-
Alexa680 in liver even at 24 hours after injection, in addition to kidney (Fig. 2.8 C). 
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Fig. 1.5 Biodistribution of Bac7(1-35)-CAM(Alexa680)PEG20k in healthy mice after i.p. injection. 
The animals were placed in prone position (A) and supine position (B); fluorescence emission in the 
regions of interest encompassing respectively the kidneys, the thorax and abdomen, were acquired at 
indicated times post-injection. The panel B on the light shows the fluorescence emission of the mouse in 
supine position at 24 h post injection and normalized with respect to the prescan acquired before peptide 
injection. (C) Ex vivo images: post-mortem images of mice at 24 hours after i.p. injection of PEGylated 
Bac7(1-35)-Alexa680. Imaging of the mice was performed immediately after sacrifice, after removal of 
the abdominal wall and normalized. A specific signal was detected in kidney, liver and peritoneal cavity 
(panel on the left); Ex vivo images of organs at 24 hours after i.p. injection of PEGylated Bac7(1-35)-
Alexa680. Imaging of the organs was performed immediately after sacrifice and normalized. A specific 
signal was detected in kidney and liver. No specific signal was detectable in spleen. The images are 
representative of one of three mice analysed that showed comparable results. 
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3.  EFFECTS of Bac7(1-35) ON CELLS OF THE HUMAN IMMUNE 
SYSTEM DURING Salmonella typhimurium INFECTION 
The aim of this part of the study was to analyze the effects of Bac7(1-35) on the 
interaction between cells of the immune system and S. typhimurium, trying to 
mimick what happens during an in vivo infection. To this purpose, experiments were 
carried out setting up a cellular model of Salmonella infection to evaluate i) the 
effect of the peptide on phagocytosis after pre-treatment of bacterial or of phagocytic 
cells with Bac7(1-35); ii) the effect of externally added peptide on survival of S. 
enterica phagocytized by human macrophage-like cells.  
 
3.1.  Cytotoxicity of Bac7(1-35) on PMA-differentiated U937 cells  
Before investigating the effects of Bac7(1-35) on biological activities of phagocytic 
cells, we determined the maximum concentrations of peptide that could be used on 
cell lines without significant toxic effects. Previous studies performed by Zanetti and 
co-workers, showed that Bac7(1-35) is not toxic to a fibroblast cell line after 60-min 
incubation up to 50 M concentration (Tomasinsig et al. 2006). Following these 
observations, the viability of PMA-differentiated U937 cells was tested after a long-
term treatment (24 h incubation) using 10, 30 and 50 M Bac7(1-35). For this assay 
we used a combination of two fluorescent probes, DiOC6 and PI, to investigate the 
type of cell response induced by the peptide. The former probe measures the 
mitochondrial transmembrane potential and is used to detect apoptotic cells, while 
the latter detects permeabilized, necrotic cells. Results indicated that treating the 
cells with 50 M peptide for 24 h decreased the cell viability mainly inducing 
necrosis in half of the cellular population; in contrast, the percentage of damaged 
cells was comparable to that of the control at lower peptide concentrations (Fig. 3.1).  
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Fig. 3.1 Flow cytometric analysis of PMA-differentiated U937 cells treated for 24 h 
with different concentrations of Bac7(1-35). Bi-parametric dot plot of U937 cell red 
fluorescence due to Pi uptake vs green fluorescence due to DiOC6 uptake. The dyes DiOC6 
and PI were added before analysis. Normal, apoptotic and necrotic cells are respectively 
enclosed in boxed regions with green, red, and cyan colours. 
 
However, considering the intracellular antimicrobial activity of Bac7(1-35), up to 50 
M the peptide did not exert any effect on phagocytosed salmonellae. On the light of 
these considerations, two concentrations of Bac7(1-35) were chosen for the 
following assays (after 3 h of peptide-treatment, or 21 h later after peptide removal 
by cell washing) 50 and 150 M and the incubation time that maintains cell viability 
at these concentrations was investigated. The results showed that after 3 h of 
treatment with 50 M peptide only % of the cells were damaged compared with 
the 6% of the peptide-untreated control; conversely, treatment of the cells with 150 
M peptide significantly increased the percentage of necrotic cells (12% vs 2% of 
untreated cells,) indicating that the peptide starts to exert a not negligible toxicity at 
this higher concentration.  
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A)                          
                                                     
                       
 
 
 
 
 
B) 
Fig 3.2. Flow cytometric analysis of U937 cells treated with Bac7(1-35) at high 
concentration (A) Bi-parametric dot plot of fluorescence emission by U937 cell due to Pi 
uptake (red fluorescence) vs DiOC6 uptake (green fluorescence). U937 cells were treated for 
3 h with 50 or 150 M Bac7(1-35) and analysed immediately thereafter or after additional 
21 h of incubation following peptide removal by cell washing. The dyes DiOC6 and PI were 
added before analysis. Normal, apoptotic and necrotic cells are respectively enclosed in 
green, red, and cyan regions. (B) Percentages of necrotic and apoptotic cells in peptide-
untreated controls and after treatment with 50 and 150 M peptide for 3 h without or with 
further 21 h incubation after peptide removal by washing. Statistical analysis carried out by 
the T-student test: p <0.05 (*) treated vs untreated cells. 
When the cells were analyzed 21 h later after removing the peptide by washing, no 
 Apoptotic cells (%) Necrotic cells (%) 
 3 h 3 h+21h 3 h 3h+21h 
no peptide 4±2 8 ± 3 2.2±1 3.83±3 
50 M Bac7(1-35) 6 ±3 7.5±2 3.2±1 3.5±2 
150 M Bac7(1-35) 8.5±4 14±4 12±4 (*) 5±2 
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further increase in the percentage of dead cells was detected by expositing the cells 
to both 50 and 150 M peptide (Fig. 3.2). This indicates that the toxic effect of 
Bac7(1-35) does not increase upon removal of the peptide.  
 
 
3. 2 Bac7(1-35) internalization into monocytic cell lines 
 
To investigate the capacity of Bac7(1-35) to inhibit the growth and kill intracellular 
salmonellae, we first evaluated the efficiency of peptide internalization and its 
cellular localization into the human U937 monocytic cell line. Alexa-tagged Bac7(1-
35) was added at a concentration of 1 µM to cultures of PMA-differentiated U937. 
After incubation for 3 h the cells were then examined by confocal laser scanning 
microscopy. Bac7(1–35) appeared to diffuse in the cytoplasm as well as in the 
nucleus (Fig 3.3).  
Confocal analysis performed with Bac7(1-35)-ALEXA680 These analyses indicated 
that the peptide was able to penetrate the cells showing a diffused distribution in the 
cell soma (Fig. 3.3). 
 
 
Fig. 3.3. Confocal analysis: Bac7(1-35) distribution into U937 cells. 
Confocal images of U937 cells showing that Bac7(1-35)-ALEXA is internalized and 
homogenously diffused. The cells (blue) were first stained with FAST DiI solution to 
decorate the cytoplasmic membrane and than treated with Bac7(1-35)-ALEXA (red) for 3 h. 
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Internalization of fluorescently-labelled peptide (in this case by conjugation with 
BODIPY) by U937 cells was further analyzed by flow cytometry. Addition of the 
quencher trypan blue, which does not penetrate within intact cells, just before analysis 
confirmed that 60% of the cell-associated fluorescence was not quenchable and thus due 
to intracellular, non-exposed peptide. The remaining 40% of the fluorescence signal was 
extracellular, as indicated by its quenching on addition of trypan blue (Fig. 3.4).  
Fig. 3.4. Bac7(1-35) uptake into U937 cells. 
Flow cytometric analyses of the cell-associated 
fluorescence, which indicates the presence of Bac7(1-
35)-BODIPY. The peptide was added to the cells for 3 h 
and then the samples were treated (blue trace) or not 
(green trace) with 1 mg/ml Trypan Blue, which quenches 
extracellular fluorescence. The auto-fluorescence of the 
cells is indicated by the black trace. The reported data 
are representative of two experiments with comparable 
results. 
. 
 
3.3  Effect of Bac7(1-35) on phagocytosis 
 
To investigate if Bac7(1-35) can modulate the phagocytic uptake of bacteria by 
macrophages, a set of phagocytosis assays was carried out by using a S. enterica 
strain expressing the green fluorescent protein (GFP), which allows detection of the 
engulfed bacteria. First of all, we determined the bacteria to cell ratio (MOI) giving 
the best number of phagocytosing cells, as evaluated by flow cytometric analysis. 
Despite the high variability of the cell response among different experiments, at 
MOI 50 the number of cells phagocytosing varied from 20% to 50%, while at MOI 
100 it ranged from 25 to 70%, but at this MOI the amount of engulfed bacteria was 
approaching a plateau (Fig. 3.5 A). Taking into account the mean intensity of 
fluorescence per phagocytosing cell as a parameter of the number of bacteria 
engulfed, it appears that at MOI 100 the fluorescence intensity increased only 
slightly compared to the intensity of fluorescence detected at MOI 50 (Fig. 3.5 B). 
For this reason, a MOI 50 was chosen as bacteria to cells ratio for the subsequent 
studies.  
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A) B) 
 
 
 
Fig. 3.5. Percentages of phagocytosing cells (A) and amount of engulfed bacteria (B) at 
different bacteri to cells ratio (MOI).  Bacteria were left in contact to U937 cells for 2 h to 
allow phagocytosis (1 h plus 1 h in the presence of gentamicin, to kill non-phagocytosed 
bacteria). Flow cytometric analysis was then performed. The percentage of phagocytosing 
cells was determined on the basis of specific morphological parameters and by measuring 
the fluorescence due to the engulfed bacteria expressing GFP. The individual results of three 
experiments are reported in panel A), while the mean the mean ± SD of three independent 
experiments is shown in panel B). 
 
The experiments of phagocytosis were carried out either by pre-incubating the cells 
with Bac7(1-35) followed by addition of untreated bacteria or, vice versa, by pre-
incubating the bacteria with the peptide followed by addition to the PMA-
differentiated U937 cells.  
The results showed that pre-treatment of macrophages with Bac7(1-35) led to an 
increase of the percentage of phagocytosing cells and of the number of bacteria 
engulfed per cell. The percentage of cells involved in phagocytosing was 48% after 
pretreatment with peptide, significantly higher with respect to peptide-untreated cells 
(36%). In this set of experiments it was also observed a slight increase (+14%) in the 
number of engulfed bacteria per cell (Fig. 3.6). 
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Fig. 3.6. Evaluation of the effect of Bac7(1-35) on pre-treated U937 cells on S. 
typhimurium phagocytosis  
U937 cells were pre-treated for 1 h with 50 M Bac7(1-35). Peptide-treated cells were then 
challenged with untreated bacteria at MOI 50. The cells were collected for flow cytometric 
analysis. The percentage of phagocytosing cells and the number of engulfed bacteria were 
determined as described above. The mean ± SD of three independent experiments is 
reported. Statistical analysis was carried out with the T-student test: p <0.05(*); 0.05> p 
>0.01 (**) for treated vs untreated cells.  
 
In contrast, pre-treatment of bacteria with Bac7(1-35) at sublethal concentrations for 1 
h, led to a lower percentage of phagocytosing cells (-15%) also accompanied by a 
decreased amount of engulfed bacteria (Fig. 3.7).  
These results suggest that Bac7(1-35) added to PMA-differentiated U937cells has a 
positive effect on phagocytosis of salmonellae. Future studies are necessary to 
understand the mechanism responsible for this effect. In contrast, pretreatment of 
bacteria with the peptide makes them less suitable to be phagocytosed by the same 
cells. 
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Fig. 3.7. Evaluation of the effect of Bac7(1-35)-pretreatment of S. typhimurium on 
phagocytosis by U937 cells. Salmonella cells were pre-treated for 1 h with 0.5 M Bac7(1-
35). Peptide-treated bacteria at MOI 50 were then added to untreated cells. At the end, 
gentamicin was added for 1 h to kill extracellular bacteria. The cells were then collected for 
flow cytometric analysis. The percentage of phagocytosing cells and the number of engulfed 
bacteria were determined as described above. The resulta are the mean ± SD of three 
independent experiments. Statistical analysis was carried out with T-student test: p <0.05(*); 
0.05> p >0.01 (**) treated vs untreated cells. 
 
3.4  Exogenously added Bac7(1-35) inhibits intracellular Salmonella survival and 
replication 
We then investigated the effects of exogenously-added Bac7(1-35) on survival and 
replication of bacteria which had infected macrophage-like cells. To this aim, PMA-
differentiated U937 cells were first incubated for 1 h with cultures of S. typhimurium 
cells (MOI 10) to allow phagocytosis, before the addition of gentamicin for 1 h to kill 
non-phagocytosed bacteria. Then PMA-differentiated U937 cells were exposed to non-
toxic concentrations of Bac7(1-35) to evaluate its capacity to reduce the number of 
intracellular vital bacteria. Preliminary experiments, carried out by using fluorescent 
GFP-expressing bacteria and Bac7(1-35)-ALEXA680, showed that bacteria were 
present in the cells and that the peptide had a diffused localization within the cells and 
could co-localize in the same cellular compartments, as established by confocal 
microscopy analyses (Fig. 3.8). The number of intracellular bacteria was counted by 
lysing the cells after 3 h incubation with 50 M Bac7(1-35). As shown in Fig. 3.9 
(panel A), the peptide caused a 43% reduction of viable bacteria (CFU/ml) rescued 
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from the lysed cells compared to cells not exposed to the peptide. This effect was more 
marked after an additional 21 h incubation of the cells after removal of the external 
peptide by washing (Fig. 3.9 panel B). When the peptide concentration was augmented 
to 150 M, a dose with initial toxic effects (see fig. 3.2) the reduction of viable bacteria 
rescued from the U937 cells was even higher. 
 
 
 
 
 
 
 
 
 
                     
 
 
 
 
 
 
 
 
Fig. 3.8 Co-localization of S. enterica-GFP and Bac7(1-35)-ALEXA680 in U937 cells. Confocal 
fluorescence microscopy of S. enterica-GFP (green, upper left), Bac7(1-35)-ALEXA (red, upper right), 
in U937 cells and image of the merged two signals (lower right).  
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Fig. 3.9. Effect of Bac7(1-35) on intracellular survival and growth of Salmonella in 
U937 cells. U937 cells were infected with S. typhimurium at a MOI of 10 for 2 h (the second 
hour in the presence of gentamicin to kill extracellular bacteria), and then incubated with 
Bac7(1-35) at 50 or 150 µM for 3 h (A) and for additional 21 h (B) after removal of the 
peptide. At the end, the cells were collected, counted, lysed and the lysate plated to count 
the number of viable bacteria. The percentage of Salmonella surviving in peptide-treated 
cells is referred to the value found in control, peptide-untreated cells taken as 100% of 
survival/growth. The horizontal dashed line indicates the percentage of intracellular viable 
bacteria after 2 h of phagocytosis, taken as 100%.  Results are mean ± SD of six 
independent experiments. Statistical analysis was carried out with the T-student test: p 
<0.05(*); 0.005> p >0.01 (**) for treated vs untreated cells. 
. 
The same type of assay was repeated using primary cells derived from human 
monocytes (MDM) differentiated with Salmonella LPS. The results obtained were 
similar to those with the U937 cells: the number of viable intracellular bacteria was 
reduced by 60% with respect to peptide-untreated control after 3 h of cell treatment 
with the peptide (Fig. 3.10, panel A). Additional 21 h of treatment after 
extracellular peptide washing, showed that Salmonella cells replicated considerably 
in untreated cells, while the bacterial growth in Bac7-(1-35) treated cells was 
almost completely inhibited at both concentrations tested ( Fig. 3.10 panel B). 
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Fig.3.10. Effect of Bac7(1-35) on intracellular survival and growth of Salmonella cells 
in macrophages derived from monocytes (MDM) 
MDM cells were infected with S. typhimurium at a MOI of 10 and the experiment was 
performed as described above. The percentage of Salmonella surviving in peptide-treated 
cells is referred to the value found in control, peptide-untreated cells taken as 100% of 
survival/growth. The horizontal dashed line indicates the percentage of intracellular viable 
bacteria after 2 h of phagocytosis, taken as 100%. Results are the mean ± SD of three 
independent experiments. Statistical analysis was carried out with the T-student test: p <0.05 
(*) for treated vs untreated cells.  
. 
These results suggest that Bac7(1-35), during Salmonella infection of pahgocytic 
cells, can penetrate the cells and exert its antibacterial activity once inside them. 
 
 
 
 
 
 
 
A) B) 
  
 
 
 
DISCUSSION
 91 
 
1. THERAPEUTICAL POTENTIAL OF BAC7(1-35) IN A MOUSE  
MODEL OF S. ENTERICA INFECTION 
 
The starting point for the development of a new class of drugs is the identification of 
a lead compound that is significantly effective not only in vitro but also in vivo in 
specific animal models. In this respect, AMPs have the potential to be developed 
into a new class of clinically useful anti-infective agents. However, in spite of their 
potent in vitro activity and modest or nul propensity to select resistant mutant strains 
(Nizet et al. 2006, Zhang et al. 2005), many AMPs perform poorly in in vivo models 
of infection.  
In view of the promising results obtained by the in vitro antibacterial activity of the 
bactenecin fragment Bac7(1-35) against several Gram-negative bacterial strains, 
including clinical isolates (Benincasa et al. 2005), here its activity was also 
evaluated in a more physiological context. In order to mimic the blood environment, 
antimicrobial assays were performed in the presence of serum or plasma. Serum and 
plasma from both mice and humans were diluted in the culture medium up to 25% 
(v/v), so as to use an intermediate condition with respect to the full potential of these 
fluids to inhibit the peptide activity (Powell et al.1992). Results showed that in the 
presence of murine blood components, Bac7(1-35) partially loses its antibacterial 
activity and its inactivation is more rapid in serum than in plasma. In an attempt to 
identify the inhibiting factor, we hypothesized that albumin could have a role in 
sequestering Bac7(1-35). In fact, it is well documented that albumin is able to bind 
antibiotics reducing their potency in vivo by decreasing their effective concentration 
(Krag-Hansen 1990; Sudlow et al. 1978). Time-killing assays performed in the 
presence of bovine serum albumin, which is homologous to the human albumin 
(Gelamo et al.2002) and has a high sequence similarity in the drug binding site I 
with the rat serum albumin (Kosa et al.1997), demonstrated that this is not the case, 
as the activity of Bac7(1-35) was not inhibited. This indicates that the peptide binds 
very weakly or not at all to serum albumin. We then investigated the role of 
proteolytic degradation as an event that could inactivate the peptide. Blood is rich of 
proteases with trypsin-like activity that can cleave at Arg residue like those present 
in the Bac7(1-35) sequence. In addition, amino- and carboxyproteases, which are 
also present in blood, can cleave the peptide at the N- and C-termini, respectively. 
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Incubation of Bac7(1-35) with murine serum and plasma demonstrated that the 
peptide is in fact degraded in both fluids, with the former showing a more rapid 
inactivation, as expected from a fluid in which the proteases of the coagulation 
cascade are activated. 
It is worth noting that the effects of human blood components on the peptide are 
quite different from those of mouse. In fact, Bac7(1-35) maintains most of its 
activity in both human serum and plasma. This is due to a greatly reduced 
degradation of the peptide. In fact, as shown by Western blot analysis, the peptide is 
still present after 72 h of incubation in human fluids. This is confirmed by LC-MS 
analyses, which showed that the peptide degradation kinetics in the human system is 
slower than in murine fluids. This difference between human and mouse fluids could 
be explained by differences in activity and specificity of the proteases there present 
(Lin et al. 2005).  
The high stability of Bac7(1-35) in human serum and plasma for several days is 
interesting also in the light of the behaviour of other AMPs in these media. Human 
-defensin hBD3 shows a reduced antibacterial activity in the presence of serum 
proteins and is partially degraded by human serum proteases after only 90 min of 
incubation (Maisetta et al. 2008); the cathelicidin-peptide LL-37 is also inhibited by 
human serum (Johansson 1998), and the insect antibacterial peptide drosocin is 
completely degraded within 4 h in both diluted human and murine sera (Hoffmann et 
al. 1999). Similar results were also obtained with pyrrhocoricin, an insect AMP that 
is degraded relatively quickly by some batches of human serum (Hoffmann et al. 
1999).  
An unexpected observation is that the activity of Bac7(1-35) seems to be potentiated 
in human plasma. This effect, although less evident, was also observed, with other 
peptides such as BMAP-27, which has a membranolytic mode of action, and with 
two shorter fragments of Bac7. This observation suggests that this improvement in 
the activity of structurally different peptides is not specific and probably is related to 
some antibacterial component contained into the plasma, whose activity is detectable 
only in synergy with the exogenously added AMP. For example, the human plasma 
contains the platelet microbicidal proteins (PMPs) (Yeaman et al. 1999), which 
could in part be released during the plasma preparation (Tammen et al. 2005) and 
then potentiate the antibacterial activity of the AMPs tested. Taken together, these 
results were encouraging and prompted us to carry out some in vivo studies for a 
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first evaluation of the therapeutic potential of Bac7(1-35). 
Before testing the protective effect of the peptide in an animal model of infection, its 
acute toxicity was investigated in mice. Bac7(1-35) shows an LD50 of 105 mg/Kg, 
and is much less toxic than cathelicidin-derived helical peptides such as BMAP-27 
and -28 (LD50 of 10-15 mg/kg) (Benincasa et al. 2003). In this respect it behaves 
similarly to other proline-rich AMPs, such as pyrrhocoricin (LD50 of 50 mg/kg) and 
drosocin (LD50 of 100 mg/kg) (Otvos 2002). This result indicated that the peptide 
can be used safety in the host even at high concentrations. 
The in vivo antibacterial activity of Bac7(1-35) was tested in a mouse model of 
infection. To this aim, we used a protocol based on intraperitoneal injection of S. 
enterica, which gives an infection resembling a typhoid fever in humans (Santos et 
al. 2001). The CBA/CA strain of mice was preferred to the more common strain 
Balb/c because of the extremely high susceptibility of the latter to Salmonella 
infection, due to lack of response by resident macrophages (Takahashi et al.1990). 
Nevertheless, the infection revealed to be very aggressive also in the CBA/CA host, 
since an injection of as few as 10
2 
CFU/ml of Salmonella caused the death of 50% of 
the animals in 10 days.  
Bac7(1-35) at a dose of 30 mg/kg showed a significant level of protection, 
prolonging the mean survival time of the treated mice and completely curing 1/3 of 
them. In addition, the peptide significantly reduced the amount of viable bacteria in 
the liver and spleen of infected mice.  
Subsequently, a preliminary pharmacokinetic study was performed using a 
fluorescent-derivative of Bac7(1-35) with an antibacterial activity comparable to that 
of the unlabelled peptide, and using the Time-Domain Optical Imaging technique. 
Optical Imaging analysis in mice suggested that the protective role showed by the 
peptide in vivo is not due to its systemic diffusion but most probably by its direct 
action in the peritoneal cavity. In fact, due to its low molecular weight, the peptide is 
rapidly excreted through the renal route, greatly decreasing its systemic availability. 
The conjugation of the peptide with the fluorescent dye Alexa to allow 
biodistribution analyses did not significantly increase its molecular weight and 
presumably does not interfere significantly with its biodistribution and efficacy. It is 
well known that mice eliminate drugs through kidney much more quickly than 
humans (Mathe et al. 2006). As no nefrotoxic compounds causing renal dysfunction 
were used to alter pharmacokinetic parameters (Mathe et al. 2006), the very rapid 
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clearance of the peptide may likely have limited its activity against pathogens after 
injection in the animals.  
However, in spite of the drawbacks of the decreased activity of Bac7(1-35) in mouse 
blood and the rapid renal clearance, the in vivo results obtained are promising and 
indicate that the antibiotic activity of Bac7(1-35) might be much higher in animal 
infection models less aggressive than that here used and might be improved by 
slowing the kinetics of its renal excretion, thereby enhancing its therapeutic index. 
 
2. BAC7(1-35) PEGYLATION TO IMPROVE ITS AVAILABILITY  
 
The half-life of a small peptide can be prolonged by increasing its size. Pegylation of 
target molecules offers this opportunity; each ethylene oxide unit that composes 
PEG associates with two to three water molecules, which results in a molecule 
behaving as if it were five to ten times as large as a polypeptide of comparable 
molecular weight (Kozlowski et al. 2001).  
Poly(ethyleneglycol) (PEG) exhibits several properties that are of relevance for 
pharmaceutical applications (Delgado et al.1992, Harris et al. 1997): i) high water 
solubility, ii) high mobility in solution; iii) lack of toxicity and immunogenicity. For 
these reasons, pegylation is one of the most promising and used strategies to 
improve the pharmacokinetic behaviour of a drug. A multitude of scientific articles 
have been published in which the effectiveness of PEG to improve half-life of a drug 
molecule was clearly demonstrated. For example, mono-PEGylation of GLP-1 
(Glucagon-like peptide) led to a 16-fold increase in plasma half-life in rats (Lee et 
al. 2005); PEG-Intron and PEGylated -interferon, marketed by Schering-Plough 
and approved by FDA in 2001 for the treatment of hepatitis C, are characterized by a 
renal clearance of 77 hours (Kozlowsky et al. 2001); recently, it has been 
demonstrated that INF- -2b exhibited a 330-fold prolonged plasma half-life in rats 
compared to the native protein (Ramon et al. 2005). On the light of these 
observations, pegylation of Bac7(1-35) was chosen as a tentative solution to improve 
its in vivo availability.  
The most used method to link PEG to proteins or peptides takes advantage of 
reactive electrophiles at the terminal end of methoxy-PEG that are suitable for 
reaction with nucleophiles in proteins. This is the so-called first generation 
PEGylation chemistry (Roberts et al. 2002), which commonly involves the amino 
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group at the N-terminus of the proteins. As the antibacterial activity of Bac7(1-35) is 
dependent on a free N-terminus (Podda et al. 2006), it was necessary to carry out the 
pegylation of the molecule via its C-terminus. To ensure a lower renal excretion of 
Bac7(1-35) and, at the same time, to maintain a good antibacterial activity, PEG 
with a molecular mass of 20k was used. 
Different strategies of pegylation were pursued to overcome difficulties that have 
been encountered with some of them. For example, for the high costs of peptide 
synthesis, it was necessary to set up pegylation strategies that allowed the use of low 
amounts of Bac7(1-35) and also, at the same time, the possibility to detect small 
amounts of the conjugate. Each pegylation strategy required several RP-HPLC and 
SDS-PAGE analyses, to control the reaction efficiency, the purification level and the 
concentration of the pegylated peptide.  
The first strategy adopted was the above mentioned first generation pegylation 
chemistry via formation of an amide bond involving the C-terminus of Bac7(1-35) 
and the amino group of an amino-methoxy-PEG. Although a discrete yield of 
product (30% of the peptide conjugated) was obtained, Bac7(1-35)-PEG20k was 
active against Salmonella only at concentrations much higher than the peptide alone. 
The presence of a long polymer chain coupled to the peptide through a very stable 
bond likely interferes with Bac7(1-35) uptake into bacterial cells, so that its residual 
antibacterial activity was probably exerted through a secondary lytic mechanism, a 
mode of action that becomes relevant at peptide concentrations in the range 32-64 
µM and that does not require penetration into the cytoplasm. This loss of activity of 
the peptide was not completely unexpected as it is well documented for other 
biomolecules after stable covalent pegylation (Veronese 2008).  
In order to allow Bac7(1-35) uptake into the bacterial cytosol, the peptide was 
pegylated via a cleavable bond that can ensure its release from the PEG molecule. 
The polymer was coupled to Bac7(1-35) via formation of an ester bond potentially 
cleavable by the esterases that are present in the blood. After a first unsuccessful 
attempt to form an ester bond with an ad hoc added C-terminal glycine residue to 
enhance the reactivity of PEG, we moved to a different strategy. This was based on 
the introduction at the C-terminus of the peptide of an additional cysteine residue 
whose SH group can selectively react by thioether ligation with the acetyl group of a 
methoxy-PEG-acetyl molecule.  
As predicted from the literature, the yield of reaction was very high (almost 80%) 
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and the pegylated peptide, Bac7(1-35)CAM-PEG20K, maintained a good 
antibacterial activity although lower than that shown by the unmodified molecule. 
To reach an efficacy comparable to the unpegylated peptide, it was necessary to pre-
incubate the conjugate with human serum to ensure the release of Bac7(1-35). 
Western blot analysis demonstrated that Bac7(1-35) started to be released from the 
PEG molecule within 8-24 h and was completely released within 72 h incubation 
both in human serum and plasma, without significant peptide degradation. These 
results demonstrate that pegylation of Bac7(1-35) may allow to obtain a compound 
that is more stable in blood, shows a reduced sensitivity to degradation by proteases 
and, at the same time, is active as the unmodified peptide after the slow release that 
occurs in the presence of serum or plasma.  
These promising in vitro results were completed by in vivo imaging experiments 
aimed at verifying if pegylation improves the Bac7(1-35) pharmacokinetic 
parameters. According to the data published in the literature on the advantages of 
pegylation (Zahnd et al. 2010; Chang et al. 2009), Bac7(1-35)CAM-PEG20K 
showed (i) a slower clearance compared with that shown by the unpegylated peptide, 
as a consequence of its increased molecular weight, (ii) an increased biodistribution 
due to its ability to join the blood circulation and (iii) a prolonged availability due to 
slow release of Bac7(1-35) from the PEG complex. 
Future investigations will provide data on the efficacy of the pegylated peptide in the 
animal model of Salmonella infection. 
 
 
3. EFFECTS OF BAC7(1-35) ON CELLS OF THE IMMUNE SYSTEM  
DURING INFECTION WITH S. ENTERICA  
 
We then investigated the effects of Bac7(1-35) on immune cells such as 
macrophages during a S. enterica infection, and its ability to exert antibacterial 
activity once having penetrated the cells.  
Initially, we extended previous observations on the effects of the peptide on 
mammalian cells, by showing that it is weakly cytotoxic to PMA-differentiated 
U937 cells even after long-term incubation and at concentrations that are much 
higher than those antibacterial (3 h at 50 µM). In addition, we confirmed that the 
peptide, added to U937-derived macrophages, was efficiently internalized into the 
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cells. In particular, Bac7(1-35) seemed to induce necrosis of the cells rather than 
apoptosis, suggesting that it probably induced surface changes that led to plasma 
membrane disruption and did not interfere with molecular mechanisms or signal 
pathways involved in the apoptotic process.  
Our attention focused on the effects of Bac7(1-35) on macrophages, since these cells 
play a central role in host defence against pathogenic microorganisms through their 
ability to rapidly recognize bacterial components, phagocytose them, and activate an 
arsenal of antimicrobial effectors. At the same time, macrophages also appear to be 
one of the preferred sites for bacterial replication in the murine model of human 
typhoid fever (Wijburg et al. 2000). Salmonellae reside intracellularly within 
macrophages (Richter-Dahlfors et al. 1997) in a specialized vacuole (see 
Introduction, paragraph 3) in which they escape from killing by components of the 
innate and humoral immune defenses and replicate starting from 4 to 8 h after 
infection (Rosenberg and Finlay 2002).  
During a systemic Salmonella infection, when the peptide is given, different possible 
situations can occur: macrophages that get first in contact with the peptide and then 
phagocytose the bacteria, macrophages that phagocytose bacteria which have 
previously come into contact with the peptide or macrophages that had already 
engulfed bacteria and then internalized Bac7(1-35).  
In the light of this scenario, our attention focused on how the presence of the peptide 
could interfere or modulate i) phagocytosis by interacting with both the 
macrophages and the bacteria ii) survival and replication of intracellular 
salmonellae.  
The effects of Bac7(1-35) on phagocytosis were studied using cytofluorimetric 
analysis and GFP-expressing Salmonellae. PMA-differentiated U937 cells and S. 
enterica cells were treated with Bac7(1-35) and the effects of the peptide studied in 
terms of variation in the percentage of phagocytosing cells and in the number of 
engulfed bacteria. In the case of macrophages pre-treated with the peptide at non-
toxic concentrations, a stimulation of the phagocytosis was clearly observed. Pre-
treating cells with Bac7(1-35) increased by 12% the percentage of phagocyting cells 
and, as consequence the number of engulfed bacteria (+ 14%). A possible 
explanation of the mechanism of activation is related to the capacity of the peptide to 
be rapidly internalized into the cells. Once inside it could activate molecular 
processes involved in the earlier phases of phagocytosis. In this context, one of the 
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main processes involved in bacterial engulfment is the activation of actin 
polymerization. Cytoskeletal changes in fact cause the cells
 
to extend pseudopods 
that then engulf the bacteria (Anderem et al. 1999). Recent findings suggest 
interactions between the actin cytoskeleton and cell membrane rafts that regulate 
membrane raft functions (Chichili and Rodgers 2009). As described by Zanetti and 
coworkers (Tomasinsig et al. 2006), Bac7(1-35) is able to interact with the lipid 
bilayers and inserts itself deeply into the lipid core of the cell membrane. In the light 
of these findings, it is possible that Bac7(1-35) could take part in the interplay 
between membrane rafts and actin cytoskeleton, promoting actin polimerization.  
In contrast to what reported above, when bacteria were exposed to Bac7(1-35) 
before phagocytosis, the percentage of phagocytosing cells and the number of 
engulfed bacteria per cell slightly but significantly decreased, suggesting that in this 
case the peptide interferes negatively with phagocytosis. This effect could be 
explained taking into consideration that Salmonella plays an active role in cell 
invasion, a role that could in someway be hampered by pre-treatment with peptide. 
There are many bacterial processes involved in the infection of host cells that could 
be modulated and could explain this result. It is known, for example, that in the first 
stage of infection, the bacterial cell assembles a needle-like structure belonging to 
the type III secretion system (see paragraph 3 of the Introduction), to deliver some 
virulence proteins into the host cells, a process that is crucial for Salmonella 
infection (Yu et al. 2010). The presence of Bac7(1-35) could interfere or delay this 
early process. Another hypothesis involves the initial recognition of microorganisms 
by macrophages, an event that is mediated by Toll-like receptors that recognize 
specific bacterial surface structures (e.g., flagella and membrane vesicles) and other 
specific antigens (Bergman et al. 2005). The interaction between the peptide and 
salmonellae cells could interfere with this recognition. 
The in vivo protective role of Bac7(1-35) against S. enterica infection suggests that 
the peptide might exert its bactericidal action also within infected cells. In this 
respect, Segall and coworkers recently demonstrated that an exogenously added 
hexapeptide inhibited Salmonella growth in a human macrophage-like cell line and 
in murine peritoneal macrophages (Su et al. 2010). Since S. enterica is a facultative 
intracellular pathogen able to invade host cells and survive within them (Richter-
Dahlfors et al. 1997), and Bac7(1-35) is able to penetrate host cells through 
macropinocitosys without killing them (Sandler et al. 2002, Tomasinsig et al. 2006), 
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we set up a series of experiments aimed at evaluating if the proline-rich peptide 
maintains its bactericidal activity against engulfed bacteria once inside the cells.    
The results obtained indicate that PMA-differentiated U937 cells that had 
phagocytosed S. enterica cells and then treated with 50 µM peptide for 3 h, showed 
a reduced number of viable bacteria recovered after lysis of the host cells with 
respect to untreated controls. This effect is even more evident when the count of the 
surviving bacteria was performed 21 h after removal of the peptide. These results 
suggest that Bac7(1-35) at 50 M enters the cells and effectively inhibits the growth 
of engulfed salmonellae within 3 h, while it presumably affects their survival at a 
longer time period (3 + 21 h) inhibiting almost completely their replication.  
The effect of the peptide on intracellular bacterial growth is dose-dependent and 
appears to be increased at a Bac7(1-35) concentration of 150 M. Although at this 
concentration the peptide starts to be toxic, the percentage of viable U937 cells 
remained high during the experiment.   
Similar results have been obtained using a second cells type: MDM cells. These are 
LPS-differentiated cells derived from monocytes isolated from human healthy 
donors and for this reason they are a model likely resembling the in vivo 
macrophages. Bac7(1-35) exerted antibacterial activity also in MDM cells and 
considerably reduced replication of intracellular salmonellae.  
What remains to be established is the mechanism of bacterial inhibition and/or 
killing. It is likely that the peptide acts directly on intracellular bacteria. However, it 
cannot be ruled out that the peptide could activate or potentiate cellular processes 
known to be involved in bacterial killing, such as production of reactive oxygen 
species and of nitric oxide, or release in the phagolysosomes of microbicidal 
substances produced by macrophages.  
Some clues support the first hypothesis. Considering the intracellular volume of 
macrophages and the exposition of the cells to 50 µM peptide, it can be estimated 
that the intracellular concentration of Bac7(1-35) is well above its microbicidal 
concentration. Although it may be that a large part of the internalized peptide is not 
in direct contact with the intracellular bacteria, it is possible that once inside cells, an 
aliquot of Bac7(1-35) enters the lysosomal vesicles and contributes to kill the 
entrapped bacteria. This hypothesis is supported by confocal analysis showing that 
the peptide seems not to localize into specific cellular compartments but is 
ubiquitously distributed inside U937 cells. 
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Overall these data indicate that Bac7(1-35) can play a role in the phagocytic process 
of macrophage-like cells and, most relevant, that it maintains its antimicrobial 
activity also once inside infected macrophages.  
 
 
  
 
 
Conclusions 
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The studies here reported allowed the evaluation of some aspects of the therapeutic 
potential of Bac7(1-35), an active fragment of the natural proline-rich AMP Bac7, to 
understand if it could be a lead compound for future development of novel 
antimicrobial agents. In this respect, our results have emphasized some desirable 
properties of the peptide: a poor toxic effect on animals and a significant protective 
effect in vivo, when used in a mouse model of infection resembling typhoid fever in 
humans. However, it also showed some weaknesses that are common to peptides 
when they are tested as drugs: a rapid excretion and a poor stability in biological 
fluids that can lead to decreased activity. A great effort was thus made to try to 
overcome these weaknesses by modifying the peptide with PEG. The first results 
were encouraging. A pegylated compound, prepared via a cleavable thioester bond, 
showed that the peptide can be released in a fully active form by esterases present in 
biological fluids increasing its in vivo biodistribution and half-life. Protection 
experiments in mice are planned to verify the therapeutic efficacy of the pegylated 
Bac7(1-35).  
In addition to pegylation, it would also be useful to evaluate other biochemical 
modifications, such as the use of unnatural amino acids, with the aim of overcoming 
the peptide degradation observed for instance in murine serum and plasma. This is 
particularly important, since many mouse models of infection are well established 
and are useful to evaluate the therapeutic potential of the peptide.  
Finally, we demonstrated that Bac7(1-35) is effective in killing salmonella cells after 
their uptake by macrophages. It could thus be interesting to evaluate if the presence 
of the PEG molecule could interfere or potentiate the activity of the peptide inside 
host cells. In this context, it would be useful to investigate the molecular 
mechanisms by which the peptide leads to killing intracellular bacteria and obtain, at 
the same time, additional information on its interaction with immune cells. 
 
 
 
 103 
 ACKNOWLEDGEMENTS 
 
 
 
Sebbene il Dottorato rappresenti una sfida impegnativa e talvolta in apparenza impossibile 
da portare avanti, ha sicuramente permesso di accrescere le mie capacità e conoscenze, 
dandomi molti spunti di riflessione. Oltre all’approfondito bagaglio scientifico, questa 
esperienza mi ha anche regalato un bellissimo periodo di amicizia, divertimento e crescita 
personale. Per cui desidero ringraziare tutte le persone che mi hanno accompagnato in 
questi tre anni di studio e di vita. 
Il Prof. Renato Gennaro, per avermi accettato nel suo gruppo e avermi materialmente 
permesso di portare avanti e concludere il mio progetto di Dottorato. 
Il Dott. Marco Scocchi, per la sua pazienza e le discussioni costruttive  
La Dott.ssa Monica Benincasa, alla quale è rivolto in particolar modo il mio 
ringraziamento, per aver creduto ancora una volta in me, avermi supportato e soprattutto 
sopportato in questi tre anni ad occhi chiusi e per aver avuto l’idea di questo progetto di 
ricerca credendoci sempre fermamente; ancora una volta la devo ringraziare per avermi 
svelato il suo prezioso sapere con grande professionalità, giudizio e immensa pazienza.  
La Dott.ssa Sabrina Pacor per avermi fatto scoprire l’interessante mondo delle cellule e 
avermi dato fiducia e attenzione durante tutto il periodo di collaborazione. 
Un grazie sincero a Marianna, un’amica e persona eccezionale nonché una brillante mente. 
Annalisa e Mariangela per aver reso il Dottorato un periodo di divertimento, gioia e 
riflessione personale e soprattutto per condividere con me un grande progetto! 
Le care e preziose amiche e colleghe Nina, Milena, Tania, Francesca, Daniela, Giulia 
nonché il Prof. Tossi per la simpatia e i brillanti spunti scientifici e Mario, per le sue perle 
italianistiche. 
Le mie grandi pazze amiche di spritz e viaggi Luisa e Francesca. 
E in ultimo ma non per ordine di importanza la mia stupenda famiglia e il Santo Umberto, 
una persona veramente rara e speciale. 
 
I would like to thank anyone who made possible this PhD programme 
 
 
 
 
 
 104 
 
  
 
 
 
References 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 105 
Aderem A, Ulevitch RJ Toll-like receptors in the induction of the innate immune 
response Nature (2000) 406: 782-787. 
Agerberth B, Lee JY, Bergman T, Carlquist M, Boman H, Mutt V, Jornvall H 
Amino acid sequence of PR-39 Eur J Biochem (1991) 202: 849-854. 
Antcheva N, Morgera F, Creatti L, Vaccari L, Pag U, Pacor S, Shai Y, Sahl HG, 
Tossi A. Artificial beta-defensin based on a minimal defensin template  Biochem 
J. (2009) 421: 435–447.  
Bader M, Sanowar S, Daley M, Schneider A, Cho U, Xu W, Klevit R, Le Moual H, 
Miller S Recognition of Antimicrobial Peptides by a Bacterial Sensor Kinase 
Cell (2005) 122: 461-472. 
Bagella L, Scocchi M, Zanetti M cDNA sequenze of three sheep myeloid 
cathelicidins FEBS Lett (1995) 376: 225-228. 
Ballico M, Drioli S, Bonora G MultiPEGs: High Molecular Weight 
Multifunctional Poly(ethylene glycol)s Assembled by a Dendrimer-Like 
Approach Eur J Organ Chem (2005) 10: 2064-2073. 
Beissewenger C Functions of antimicrobial peptides in host defense and 
immunity Curr Prot and Pept Sci (2005) 6: 255-264. 
Bellomio A, Vincent PA, Arcuri BF, Farias RN, Morero RD Microcin J25 has dual 
and independent mechanisms of action in Escherichia coli: RNA polymerase 
inhibition and increased superoxide production J Bacteriol (2007) 189: 4180-
4186. 
Bergman M, Cummings L, Rassoulian Barret S, Smith K, Lara C, Aderem A, 
Cookson B CD4
+
 T Cells and Toll-Like Receptors Recognize Salmonella 
Antigens Expressed in Bacterial Surface J. Immunol (2005). 73: 1350-1356. 
Benincasa M, Skerlavaj B, Gennaro R, Pellegrini A, Zanetti M In vitro and in vivo 
antimicrobial activities of two alpha helical cathelicidin peptides and of their 
synthetic analogs Peptides (2003) 24: 1723-1731. 
Benincasa M, Scocchi M, Podda E, Skerlavaj B, Dolzani L, Gennaro R, 
Antimicrobial activity of Bac7 fragments against drug-resistant clinical isolates 
Pept (2004) 25: 2055-2061.  
Benincasa M, Pacor S, Gennaro R, Scocchi M Rapid and reliable detection of 
antimicrobial peptide penetration into gram-negative bacteria based on 
fluorescence quenching J Antimicrob Agent Chemother (2009) 53: 3501-3504. 
Bennet V, Simmons M, Analysis of fluorescently labeled substance P analogs: 
binding, imaging and receptor activation BMC Chem Biol (2001) 1: 1. 
Bessalle R, Kapitkovsky A, Gorea A, Shalit I, Fridkin M All-D magainin: chirality, 
antimicrobial activity and proteolytic resistance FEBS Lett (1990) 274: 151-155. 
Birge, R.B., and D.S. Ucker. Innate apoptotic immunity: the calming touch of 
death. Cell Death Differ (2008)15:1096-102. 
Boman HG, Agerberth B, Boman A, Mechanism of action on Escherichia coli of 
cecropin P1 and PR-39, two antibacterial peptides from pig intestine Infect 
Immun (1993) 61: 2978-2984. 
 
 106 
Boman HG Peptide antibiotics and their role in innate immunity Annu Rev 
Immunol (1995) 13: 61-92. 
Bowdish D, Davidson D, Hancock R Immunomodulatory properties of defensins 
and cathelicidins Curr TopicsMicrobiol Immunol (2006) 306: 27-66. 
Blocker A, Jouihri N, Larquet E, Niebuhr K et al The tripartite type III secreton 
of Shigella flexneri inserts IpaB and IpaC into host membranes J Cell Biol 
(1999) 147: 683-693. 
Bracci L, Falciani C, Lelli B, Lozzi L, Runci Y, Pini A, De Montis MG, 
Tagliamonte A, Neri P. Synthetic peptides in the form of dendrimers become 
resistant to protease activity. J Biol Chem. (2003) 278: 46590-46595. 
Brogden KA, Kalfa V, Ackermann M, Palmquist D, McCray Jr, Tack B The ovine 
cathelicidin SMAP 29 kills ovine respiratory pathogens in vitro and in an ovine 
model of pulmonary Infection Antimicrob Agent Chemother (2001) 45: 331-334. 
Brogden KA Antimicrobial peptides: pore formers or metabolic inhibitors in 
bacteria? Nat Rev Microbiol (2005) 3: 238-250. 
Brombacher, F. The role of interleukin-13 in infectious diseases and allergy 
BioEssays (2000) 22: 646-656. 
Brown KL, Hancock RE cationic host defense (antimicrobial) peptides Curr Opin 
Immunol (2006) 18: 24-31. 
Buchmeier NA, Heffron F Inhibition of macrophage phagosome-lysosome fusion 
by Salmonella typhimurium Infect Immunol (1991) 59: 2232-2238. 
Bulet P, Dimarcq JL, Hetru C, Lagueux , Charlet M, Hegy G, van Dorsselaer A, 
Hoffman n JA A novel inducible antibacterial peptide Drosophila carries an O-
glycosylated substitution J Biol Chem (1993) 268: 14893-14897. 
Bulet P, Hetru C, Dimarcq JL, Hoffmann D Antimicrobial peptides in insects; 
structure and function Dev Comp Immunol (1999) 23: 329-344. 
Cabras T, Longhi R, Secundo F, Nocca G, Conti S, Polonelli L, Fanali C, Inzitari R, 
Petruzzelli R, Messana I, Castagnola M, Vitali A Structural and functional 
characterization of the porcine proline-rich antifungal peptide SP-B isolated 
from salivary gland granules J Pept Sci (2008) 14: 251-260. 
Campoy S, Jara M, Busquet N, Perez De Rozas AM, Badiola I, Barbe J Role of the 
high affinity zinc uptake znuABC system in Sakmonella enterica serovar 
typhimurium virulence Infect Immun (2002) 70: 4721-4725. 
Cardelli J  Phagocytosis and macropinocytosis in Dictyostelium: 
Phosphoinositide- based processes, biochemically distinct. Traffic (2001) 2:311-
320. 
Carretero M, Escamez MJ, Garcia M, Duarte B, Holguin A, Retamosa L In vitro 
and in vivowound healing-promoting activities of human cathelicidin LL-37 J 
Invest Dermatol (2008) 223-236. 
Casteels P, Ampe C, Jacobs F, Vaeck M, Tempst P Host defense peptides from 
invertebrates- emerging antimicrobial strategies Immunobiol (1989)211: 315-
322. 
 107 
Casteels P, Romagnolo J, Castle M, Casteels-Josson K, Erdjument-Bromage H, 
Tempst P Biodiversity of apidaecin-type peptide antibiotics. Prospects of 
manipulating the antibacterial spectrum and combating acquired resistance. J 
Biol Chem. (1994)  269: 26107-15. 
Chichili G, Rodgers W Cytoskeleton-membrane interactions in membrane raft 
structure Cell Mol Life Sci (2009) 66: 2319-2328. 
Chromek M, Slamova Z, Bergman P, Kovacs L, Podrackà L, Ehren I, Hokfelt T, 
Gallo B, Agerberth B, Brauner A The antimicrobial peptide cathelicidin protects 
the urinary tract against invasive bacterial infection Nat Med (2006) 12: 636-
641. 
Cirioni O, Giacometti A, Ghiselli R, Bergnach C, Orlando F, Silvestri C, 
Mocchegiani F, Licci A, Skerlavaj B, Rocchi M, Saba V, Zanetti M, Scalise G LL-
37 Protects rats against lethal sepsis caused by Gram-negative bacteria 
Antimicrob Pept (2006) 50: 1672-1679. 
Cociancich S, Dupont A, Hegy G, Lanot R, Holder F, Hetru C, Hoffmann JA, Bulet 
P Novel inducible antibacterial peptides from hemipteran insect, the sap-
sucking bug Pyrrhocoris apterus Biochem (1994) 300: 567-575. 
Conner SD, Schmid SL Regulated portals of entry into the cells Nature (2003) 
422: 37-44. 
Coombes BK, Valdez Y, Finlay BB Expression and secretion of Salmonella 
pathogenicity island-2 virulence genes in response to acidification exhibit 
differential requirements of a functional type III secretion apparatus and SsaL  
J Biol Chem  (2004) 279: 49804-49815. 
Cotter PD, Hill C, Ross RP Bacterial lantibiotics: strategies to improve 
therapeutic potential Curr Prot Pept Sci (2005) 6: 61-75. 
Crawford R, Rosales-Reyes R, Ramirez-Aguilar M, Chapa-Azuela O, Aranda C, 
Gunn J gallstones play a significant role in Salmonella spp. Gallbladder 
colonization and carriage PNAS (2010) 107:4353-4358. 
Crump JA, Luby SP, Mintz ED The global burden of typhoid fever Bull World 
Health Organ (2004) 82: 346. 
Dartois V, Sanchez-Quesada J, Cabezas E, Chi E, Dubbelde C, Dunn C et al 
Systemic antibacterial activity of novel synthetic cyclic peptides Antimicrob 
Agents Chemother (2005) 49: 3302-3310. 
Dathe M, Nikolenjo H, Klose J, Bienert M Cyclization increases the antimicrobial 
activity and selectivity of arginine- and tryptophan- containing hexapeptides 
Biochem (2004) 43: 9140-9150. 
Dawson P, Muir T, Clark-Lewis I, Kent SBH, Synthesis of proteins by native 
chemical ligation Science (1994) 266: 766-779. 
Destoumieux D, Bulet P, Strub JM, Van Dorsselaer A, Bachere E, Romestand B 
Stylicins, a new family of antimicrobial peptides from the Pacific blue shrimp 
Eur J Biochem (2000) 266: 335-346. 
Doherty TM, Kastelein S, Menon S, Andrade S, Coffman RL Modulation of 
murine macrophage function by IL-13 (1993) J. Immunol 151: 7151-7160. 
 
 108 
Drecktrah D, Knodler L, Galbraith K, Steele-Mortimer O The Salmonella SPI1 
effector SopB stimulates nitric oxide production long after invasion Cell 
Microbiol (2005) 7: 105-113. 
Eilsbach P What is the real role of antimicrobial polypeptides that can mediate 
several other inflammatory responses? J Clin Invest (2003) 111: 1643-1645. 
Eriksson S, Lucchini S, Thompson A, Rhen M, Hinton JC Untravelling the biology 
of macrophage infection by gene expression profiling of intracellular 
Salmonella enterica Mol Microbiol (2003) 47: 103-118. 
Ernst R, Guina T, Miller S Salmonella typhimurium outer membrane 
remodeling: role in resistance to host innate immunity. Microbes Infect. (2001) 
3:1327–1334. 
Falciani C, Fabbrini M, Pini A, Lozzi L, Lelli B, Pileri S, Brunetti J, Bindi S, Scali 
S, Bracci L. Synthesis and biological activity of stable branched neurotensin 
peptides for tumor targeting. Mol Cancer Ther (2007) 6: 2441-2448. 
Falkow, S. Salmonellosis: host immune responses and bacterial virulence 
determinants. Annu Rev Immunol (1996) 14: 533–561. 
Field D, Quigley L, O’Connor P, Rea M, Daly K, Cotter P, Hill C, Rose P Studies 
with bioengineered Nisin peptides highlight the broad-spectrum potency of 
Nisin V Microb Biotech (2010) 3: 473-486.  
Fogueri L, Singh S Smart polymers for controlled delivery of proteins and 
peptides: a review of patents Recent Pat Drug Deliv Formul (2009) 3: 40-48. 
Fritsche TR, Rhomberg PR, Sader HS, Jones RN Antimicrobial activity of 
omiganan pentahydrochloride tested against contemporary bacterial pathogens 
commonly responsible for catheter-associated infections J Antimicrob Chemother 
(2008) 61: 1092-1098. 
Gallant P, Belenkov A, Ma G, Lesage F, Wang Y, Hall D, Mcintosh L A 
quantitative time domain optical imager for small animals in vivo fluorescence 
studies OSA Biomedical Optics Topicals Meetings WD2 (2004) 
Ganz T, Lehrer RI Antimicrobial peptides of vertebrates Curr Opin Immunol 
(1998) 10:41-50. 
Ganz T Defensins: antimicrobial peptides of Innate Immunity Nat Rev Immunol 
(2003) 3: 710-720. 
Gelamo, E, Silva P., Imasato H., and Tabak M. Interaction of bovine (BSA) and 
human (HSA) serum albumins with ionic surfactants: spectroscopy and 
modelling Biochim Biophys Acta (2002) 1594: 84-99 
Gennaro R, Skerlavaj B, Romeo D, Purification, composition and activity of two 
bactenecins, antibacterial peptides of bovine neutrophils Infect Immun (1989) 57: 
3142-3148. 
Gennaro R, Zanetti M Structural features and biological activities of the 
cathelicidin-  derived antimicrobial peptides Biopol (2000) 55: 31-49. 
Gennaro R, Zanetti M, Benincasa M, Podda E, Miani M Pro-rich antimicrobial 
peptides from animals: structure, biological functions, mechanism of action 
Curr Pharm Design (2002) 8: 763-778. 
 109 
Ghiselli R, Giacometti A, Cirioni O, Circo R, Mocchegiani F, Skerlavaj B, D’Amato 
G, Scalise G, Zanetti M Saba V Neutralization of endotoxin in vitro and in vivo by 
Bac7(1-35), a proline-rich antibacterial peptide Shock (2003) 19: 577-581. 
Giacometti A, Cirioni O, Ghiselli R, Mocchegiani F et al Interaction of 
Antimicrobial peptide temporin L with Lipopolysaccharide in vitro and in 
experimental rat models of septic shock caused by Gram-negative bacteria 
Antimicrob Agent Chemother (2006) 50: 2478-2486. 
Gordon S Macrophages and the immune system Fundam Immunol (1999) 
Lippincott-Raven Publishers, Philidelphia  533-545. 
Gordon S Alternative activation of Macrophages Nature (2003) 3: 23-35. 
Gordon S, Taylor PR Monocyte and macrophage heterogeneity Nat Rev Immunol 
(2005) 5: 953-964. 
Gordon S, Martinez F Alternative activation of Macrophages: mechanism and 
functions Immun (2010) 32: 593-604. 
Greaves, DR, and Gordon S Thematic Review Series. The immune system and 
atherogenesis. J Lipid Res (2005) 46: 11–20. 
Gueguen Y, Bernard R, Julie F, Paulina S, Delphine DG, Fanck V, Philippe B, 
Evelyne B Oyster hemocytes express a proline-rich peptide displaying 
synergistic antimicrobial activity with a defensin Mol Immunol (2009) 46: 516-
522. 
Guiotto A, Pozzobon M, Canevari M, Manganelli R, Scarin M, Veronese FM 
PEGylation of the antimicrobial peptide nisin A: problems and perspectives 
Farmaco (2003) 58: 45-50. 
Gulig, PA Pathogenesis of systemic disease. In: Escherichia coli and Salmonella 
typhimurium: Cellular and Molecular Biology  Neidhardt, F.C. et al., (eds). 
Washington, DC: American Society for Microbiology Press (1996): 2774-2802. 
Gunn J, Miller S PhoP-PhoQ activates transcription of pmrAB encoding a two-
component regulatory system involved in Salmonella typhimurium 
antimicrobial peptide resistance J Bacteriol (1996) 178: 6857-6864. 
Gutierrez M Salmonella vacuole maturation: PIKfyve leads the way The EMBO J 
(2010) 29: 1316-1317.  
Hallam S, Escorcio-Correio M, Soper R, Schulteiss A, Hagemann T Activated 
macrophages in the tumour microenvironment – dancing to the tune of TLR 
and NF-κB J Pathol (2009) 219:143-152. 
Hancock RE Mode of action of the new antibiotic for Gram-positive pathogens 
daptomycin: comparison with cationic antimicrobial peptides and lipopeptides 
Biochim Biophys Acta (2006) 1758: 1215-1223. 
Harris JM, Martin N, Modi M Pegylation: a novel process for modifying 
pharmacokinatics Clin Pharmacokinet (2001) 40: 539-551. 
Helborn JD, Nilsson MF, Kratz G, Weber G, Sorensen O, Borregaard N, Stahle-
Backdahl M The cathelicidin anti-microbial peptide LL-37 is involved in re-
epithelialization of human skin wounds and is lacking in chronic ulcer 
epithelium J Invest Dermatol (2003) 120: 379-389. 
 110 
Hersh D, Monack M, Smith N, Ghori S, Falkow S, Zychlinsky A The Salmonella 
invasion SipB induces macrophage apoptosis by binding to caspase-1 Proc Natl 
Acad Sci (1999) 96: 2396-2401. 
Hoffmann R, Bulet P, Urge L, Otvos L Jr Range of activity and metabolic stability 
of synthetic antibacterial glycopeptides from insects Biochim Biophys Acta 
(1999)1426: 459–467. 
Hoffmeier S, Burk O, von Richter O, Arnold HP, Brokmoller J, Johne A, Gerloff T, 
Roots I, Eichelbaum M, Brinkmann U Functional polymorphisms of the human 
multidrug-resistance gene: multiple sequence variations and correlation of one 
allele with P-glycoprotein expression and activity in vivo Proc Natl Acad Sci 
(2000) 97: 3473-3478. 
Hormaeche CE, Fahrenkrog R, Pettifor A, Brock J Acquired immunity in murine 
salmonellosis Microbiol Rev (1981) 43: 547-554. 
Hueck CJ Type III protein secretion systems in bacterial pathogens of animal 
and plants Microbiol Mol Biol Rev (1998) 62: 379-433. 
Huttener KM, Lambeth MR, Burkin HR, Burkin DJ, Broad TE Localization and 
genomic organization of sheep antimicrobial peptide genes Gene (1998) 206: 85-
91. 
Ibarra A, Steele-Mortimer O Salmonella the ultimate insider Salmonella 
virulence factors that modulate intracellular survival Cell Microbiol (2009) 11: 
1579-1586. 
Imura Y, Nishida M, Matsuzaki K Action mechanism of PEgylated magainin 2 
analogue peptide Biochim Biophys Acta (2007) 1768: 2578-85.  
Imura Y, Nishida M, Ogawa Y, Takakura Y, Matsuzaki K Action mechanism of 
PEgylated  tachyplesin I and effects of PEGylation Biochim Biophys Acta (2007) 
1768: 1160-1169.  
Jain C Macrophages and monocytes Essential of veterinary hematology (1993) 
5:269-275. 
James PE, Madhani M, Ross C, Klei L, Barchowsky A, Swartz HM Tissue hypoxia 
during bacterial sepsis is attenuated by PR-39, an antibacterial peptide Adv Exp 
Med Biol (2003) 530: 645-652. 
Jones B. D., and Falcow S Salmonellosis: host immune responses and bacterial 
virulence determinants. Annu Rev Immunol (1996)14: 533-561 
Khandare J, Kolhe P, Pillai O, Kannan S, Lieh-Lai M, Kannan RM Synthesis, 
cellular transport, and activity of polyamidoamine dendrimer-
methylprednisolone conjugates Bioconjugate Chem (2005) 16: 330-337. 
Khandare J, Minko T Polymer-drug conjugates: Progress in polymeric prodrugs 
Prog Polym Sci (2006) 7: 359-397.  
Kindrachuk J, Scruten E, Attah-Poku S, Potter A, Babiuk A, Bell K, Griebel P, 
Napper S Stability, toxicity, and biological activity of host defense peptide 
BMAP28 and its inversed and retro-inversed isomers Biopolym Pept Sci (2010) 
96: 14-24. 
Kopitar M, Ritonja A, Popovic T, Gabrijelcic D, Krizaj I, Turk V A  new type of 
low –molecular mass cysteine proteinase inhibitor from pig leukocytes Biol 
 111 
Chem Hoppe-Seyler (1989) 370: 1145-1151. 
Kosa T, Maruyama T, Otarigi M Species differences of serum albumins: I Drug 
binding site Pharm Res(NY) (1997) 14: 1607-1612. 
Kozlowski A, Charles SA, Harris JM Development of pegylated interferons for 
the treatment of chronic hepatitis C. BioDrugs (2001) 15: 419-429. 
Kragh-Hansen U: Structure and ligand binding properties of human serum 
albumin. Dan Med Bull 1990, 37:57-84. 
Krutzik SR, Tan B, Li H TLR activation triggers the rapid differentiation of 
monocytes into macrophages and dendritic cell. Nat Med (2005) 11: 653-60. 
Kuipers BJ, Gruppen H Prediction of molar extinction coefficients of proteins 
and peptides using UV absorption of the constituent amino acids at 214 nm to 
enable quantitative reverse phase high-performance liquid chromatography 
mass spectrometry analysis J Agric Food Chem (2007) 55: 5445-5451. 
Lai Y, Gallo R AMPed up immunity: how antimicrobial peptides have multiple 
roles in immune defense Trends Immunol (2009) 30: 131-141. 
Lee SH, Lee S, Youn Y, Na D, Chae S, Byun Y, Lee KC Synthesis, 
characterization, and pharmacokinetic studies of PEGylated glucagon-like 
peptide-1 Bioconjug Chem (2005) 16: 377-382. 
Lemaster, J.J. Necroapoptosis and the mitochondrial permeability transition: 
shared pathways to necrosis and apoptosis. Amer J Physiol (1999) 276: G1-G6. 
Levin M, Quint PA, Goldstein B, Barton P, Bradley JS Recombinant 
bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment 
for children with severe meningococcal sepsis: a randomised trial Lancet (2000) 
356: 961–967. 
Li J, Post M, Volk R, Gao Y, Li M, Metais C, Sato K, Tsai J, Aird W, Rosenberg 
RD, Hampton TG, Sellke F, Carmeliet P, Simons M PR39, a peptide regulator of 
angiogenesis Nat Med (2000) 6:49- 55. 
Li J, Xu X, Yu H, Yang H, Huang Z, Lai R Direct antimicrobial activities of PR-
bombesin Life Sci (2003) 78: 1953-1956. 
Li J, Nation RL, Tunridge JD Colistin: the re-emerging antibiotic for multidrug 
resistant Gram-negative bacterial Lancet Infect Dis (2005) 6: 589-601. 
Li B, Meghan S, Indumathi M, Boopathy R, Duysen E, Masson P, Lockridge O 
Butyrylcholinesterase, paraoxonase, and albumin esterase, but not 
carboxylesterase, are present in human plasma Biochem Pharm (2005) 70: 1673-
1684. 
Liu Z, Deshazer H, Amanda JR, Chen K, Zhou C, Kallenbach NR Multivalent 
antimicrobial peptides from a reactive polymer scaffold J Med Chem (2006) 49: 
3436-3439. 
Lopez-Garcia B, Lee P, Yamasaki K, Gallo R Anti-fungal activity of cathelicidins 
and their potential role in Candida albicans skin infection J Inv Derm (2005) 125: 
108-115. 
Mahdani M, Barchowsky A, Klei L, Ross CR, Jackson SK, Swartz HM, James PE 
Antibacterial peptide PR-39 affects local nitric oxide and preserves tissue 
 112 
oxygenation in the liver during septic shock Biochim Biophys Acta (2002) 1588: 
232-240. 
Maisetta G, Di Luca M, Esin S, Florio W, Brancatisano F, Campa M, Batoni G 
Evaluation of the inhibitory effects of human serum components on 
bactericidal activity of human beta defensin 3 Peptides (2008) 29: 1-6. 
Marr AK, Goodrham W, Bains M, Hancock REW Antibacterial peptides for 
therapeutic use: obstacles and realistic outlook Curr Opin Pharm (2006) 6: 468-
472. 
Mathe A, Komka K, Forczig M, Szabo D, Anderlik P, Rozgonyi F The effect of 
different doses of cisplatin on the pharmacokinetic parameters of cefepime in 
mice Lab Anim (2006) 40: 296-300. 
Mattiuzzo M, Bandiera A, Gennaro R, benincasa M, Pacor S, Antcheva N, Scocchi 
M, Role of the Escharichia coli SbmA in the antimicrobial activity of proline-
rich peptides (2007) Mol Microbiol 66: 151-163. 
Miller S, Mekalanos J Constitutive expression of the PhoP regulon attenuates 
Salmonella virulence and survival within macrophages J Bacteriol (1990) 172: 
2485-2490. 
Monak D, Raupach A, Hromockyj A, Falkow S Salmonella typhimurium invasion 
induces apoptosis in infected macrophages Proc Natl Acad Sci (1996) 93: 9833-
9838. 
Monak D, Bouley DM, Falkow S Salmonella typhimurium persists within 
macrophages in the mesenteric lymph nodes of chronically infected Nramp1+/+ 
mice andcan be reactivated by IFNgamma neutralization J Exp Med (2004) 
199:231-241. 
Morpurgo V, Veronese FM Conjugates of Peptides and Proteins Mol Biol 
Methods (2004) 23: 45-70. 
Mosser D The many faces of macrophage activation J Leuk Biol (2003) 73:209-
212 
Nath G, Yogesh K, Murya P, Gulati K, Srivastava R, Tripathi K Does Salmonella 
Typhi primarily reside in the liver of chronic typhoid carriers? J Infect Dev 
Ctries (2010) 4: 259-261. 
National Committee for Clinical Laboratory Standards Methods for Antimicrobial 
Susceptibility Testing of Anaerobic Bacteria Fifth Edition: Approved Standard 
M11-A5 (2000) NCCLS, Villanova, PA, USA. 
Nizet V Antimicrobial peptide resistance mechanisms of human bacterial 
pathogens Curr Issue Mol Biol (2006) 8: 11-26. 
Okarvi S Recent development in 
99
Tc
m
-labelled-peptide-based 
radiopharmaceuticals: an overview Nucl Med Comm (1999) 20: 1093-1112. 
Oren Z, Shai Y Cyclization of cytolytic amphipathic alpha-helical peptide and 
its diastereomer: effect on structure, interaction with model membranes, and 
biological function Biochem (2000) 39: 6103-6114. 
Ouellette AJ Paneth Cell α-Defensin Synthesis and Function Curr Topics Microb 
and Immunol (2006) 306: 1-25.  
 113 
Otvos L Jr Antibacterial peptides isolated from insects J Peptide Sci (2000) 
6:497-511. 
Otvos L The short proline-rich antibacterial peptide family Cell Mol Life Sci 
(2002)59: 1138-1150. 
Pakkala M, Hekim C, Soininen P, Leinonen J, Koistinen H, Weisell J, Stenman U, 
Vepsalainen J, Narvanen A Activity and stability of human kalikrein-2-specific 
linear and cyclic peptide inhibitors J Pepti Sci (2007) 13: 348-353. 
Paquette DW, Simpson D, Friden P, Braman V, Williams R Safety and clinical 
effects of topical histatin gels in humans with experimental gingivitis J Clin 
Periodont (2002) 29: 1051-1058. 
Pasut G, Veronese F PEGylation of Proteins as Tailored Chemistry for Optimized 
Bioconjugates Adv  Polym Sci (2006) Volume (192): 95-134. 
Pini A, Falciani C, Bracci L Branched peptides as therapeutics Curr Protein Pept 
Sci (2008) 9: 468-477. 
Podda E, Benincasa M, Pacor S, Micali F, Mattiuzzo M, Gennaro R, Scocchi M, 
Dual mode of action of Bac7 a proline-rich peptide Biochim Biophysics Acta. 
(2006) 1760:1732-1740. 
Powell, MF, Grey H, Gaeta F, Sette A, Colon S Peptide stability in drug 
development: A comparison of peptide reactivity in different biological media J 
Pharm Sci (1992) 81:731–735. 
Prantig M, Negrea A, Rhen M, Andersson D Mechanism and Fitness Costs of PR-
39 Resistance in Salmonella enterica Serovar Typhimurium LT2 Antimicr 
Agents Chemother (2008) 52: 2734–2741. 
Pungercar J, Strukelj B, Kopitar G, Renko M, Lenarcic B, Gubensek F, Turk V 
Molecular cloning of a putative homolog of proline/arginine-rich antibacterial 
peptides from porcine bone marrow FEBS Lett (1993) 336: 284-288. 
Ramon J, Saez V, Baez R, Aldana R, Hardy E PEGylated interferon-alpha2b: a 
branched 40k polyethylene glycol derivative (2005) 22: 1374-1386. 
Rathman M, Barker LP, Falkow S The unique trafficking pattern of Salmonella 
typhimurium containing phagosomes in murine macrophages is independent of 
the mechanism of bacterial entry Infect Immun  (1997) 65: 1475-1485. 
Reddy KV, Yedery R, Aranha C Antimicrobial peptides: premises and promises 
Int J Antimicrob Agents (2004) 24: 536-547. 
Richter-Dahlfors A, Buchan A, Finlay B, Murine Salmonellosis Studied by 
Confocal Microscopy: Salmonella typhimurium Resides Intracellularly Inside 
Macrophages and Exerts a Cytotoxic Effect on Phagocytes In Vivo J Exp Med 
(1997) 186: 569-580. 
Roberts M, Bentley M, Harris M Chemistry for peptide and protein PEGylation 
Adv Drug Deliv (2002) 54: 459-476. 
Rolland JL, Abdelouahab M, Dupont J, Lefevre F, Bachère E, Romestand B. 
Stylicins, a new family of antimicrobial peptides from the Pacific blue shrimp 
Litopenaeus stylirostris. Mol. Immunol. (2010)47: 1269-1277. 
Rosenberg CM, Finlay B Macrophages inhibit Salmonella Typhimurium 
 114 
replication through MEK/ERK kinase and phagocyte NADPH oxidase 
activities J Biol Chem (2002) 277: 18753-18762. 
Rosengren KJ, Goransson U, Otvos L, Craik D Cyclization of pyrrhocoricin 
retains structural elements crucial for the antimicrobial activity of the native 
peptide Pept Sci (2004) 76: 446-458. 
Sader H, Fedler K, Rennie R, Stevens S, Jones R Omiganan Pentahydrochloride 
(MBI 226), a topical 12-amino-acid cationic peptide: spectrum of antimicrobial 
activity and measurements of bactericidal activity Antimicrob Agent Chemother 
(2004) 48: 3112-3118. 
Sadler K, Eom KD, Yang JL, Dimitrova Y, Tam JP, Translocating proline-rich 
peptides from the antimicrobial peptide bactenecin 7 Biochem (2002) 41: 14150-
14157. 
Salcedo SP, Noursadeghi M, Cohen J, Holden DW Intracellular replication of 
Salmonella typhimurium strains in specific subsets of splenic macrophages in 
vivo Cell Microbiol (2001)  3: 587–597. 
Santos RL, Zhang S, Tsolis R, Kingsley R, Adams G, Baumier A Animal models of 
Salmonella infections: enteritis versus typhoid fever Microb infect (2001) 3: 
1335-1344. 
Santos RL, Zhang S, Tsolis R, Braumler A, Adams L Morphologic and molecular 
characterization of Salmonella typhimurium infection in neonatal calves Vet 
Pathol (2002) 39: 200-215. 
Schnapp D, Kemp GD, Smith VJ Purification and characterization of a proline-
rich antibacterial peptide, with sequence similarity to bactenecin-7, from the 
haemocytes of the shore crab Carcinus maenas Eur J Biochem 240: 532-539. 
Scocchi M, Wang S, Gennaro R, Zanetti M Cloning and analysis of a tran script 
derived from two contiguous genes of the cathelicidin family Biochim Biophys 
Acta (1998) 3: 393-396 
Scocchi M, Skerlavaj B, Romeo D, Gennaro R Proteolytic cleavage by neutrophil 
elastase converts inactive storage proforms to antibacterial bactenecins (1992) 
53: 1432-1033. 
Scocchi M, Mattiuzzo M, Benincasa M, Antcheva N, Tossi A, Gennaro R 
Investigating the mode of action of proline-rich antimicrobial peptides using a 
genetic approach: a tool to identify new bacterial targets amenable to the 
design of novel antibiotics Methods Mol Biol (2008) 494: 161-176. 
Scocchi M, Luthy C, Decarli P, Mignogna G, Christen P, Gennaro R The proline-
rich antibacterial peptide Bac7 binds to and inhibits in vitro the molecular 
chaperone DnaK Int J Pept Res Therapeut (2009) 15: 147-155. 
Scocchi M, Tossi A, Gennaro R proline-rich Antimicrobial Peptides: Converging 
to a Non-Lytic Mechanism of Action (2011) article in press.  
Sergi M, Carboi F, Maullu C, Orsini G, Tonon G Pegylated Protein Drugs: Basic 
Science and Clinical Applications (2009) Birkhauser : 75-76. 
Shai Y Mode of action of membrane active antimicrobial peptides Biopol (2002) 
66: 236-248. 
 
 115 
Shai Y, Mechanism of the binding, insertion and destabilization of phospholipid 
bilayer membranes by alpha-helical antimicrobial and cell non-selective 
membrane-lytic peptides (1999) Biochem Biophysics Acta 1462: 55-70. 
Shagger H Tricine-SDS-PAGE  Nature Protocols  (2006) 1: 418-428. 
Shamova O, Brodgen KA, Zhao C, Nguyen T, Kokryakov VN, Lehrer RI 
Purification and properties of proline-rich antimicrobial peptides from sheep 
and goat leukocytes Infect Immun (1999) 67: 4106-4111. 
Shi J, Ross CR, Chengappa MM, Sylte MJ, McVey DS, Blecha F Antibacterial 
activity of a synthetic peptide (PR-26) derived from PR-39, a proline-arginine-
rich neutrophil antimicrobial peptide Antimicrob Agents Chemother (1996) 40: 
115-121. 
Sinnott CR, Teall AJ Persistent gallbladder carriage of Salmonella typhi Lancet 
(1987)1: 976. 
Stein M, Keshav S, Harris N, Gordon S Interleukin 4 potently enhances murine 
macrophage mannose receptor activity: A marker of alternative immunologic 
macrophage activation J Ex  Med (1992)  176: 287-292. 
Stromstedt A, Pasuleti M, Schmidtchen A, Malmsten M Evaluation of strategies 
for improving proteolytic resistance of antimicrobial peptides by using variants 
of EFK17, an internal segment of LL-37 Antimicrob Agents Chemother (2009) 53: 
593-602. 
Su LY, Willner D, Segall M An Antimicrobial peptide that targets DNA repair 
intermediates in vitro inhibits Salmonella growth within murine macrophages 
Antimicrob Agents Chemother (2010) 54: 1888-1899. 
Subbalakshmi C, Sitaram N Mechanism of antimicrobial action of indolicidin 
Microbiol Lett (1998) 160: 91-96. 
Sudlow G, Birkett DJ, Wade DN: The characterization of two specific drug 
binding sites on human serum albumin. Mol Pharmacol 1975, 11:824-832. 
Sun X, Yang Z, Li S, Tan Y, Zhang N, Wang X, Yagi S, Yoshioka T, Takimoto A, 
Mitsushima K, Suginaka A, Frenkel EP, Hoffman RM In vivo efficacy of 
recombinant methioninase is enhanced by the combination of polyethylene 
glycol conjugations and pyridoxal 5’-phosphate supplementation Cancer Res 
(2003) 63: 8377-8383. 
Takahashi K, Naito M, Takeya M The nature of resident macrophages J Leuk Biol 
(1990) 47: 195-205. 
Takeda K, Kaisho T, Akira S Toll-like receptors Annu Rev Immunol (2003) 21: 
335-376. 
Tammen H, Schulte I, Hess R Peptidomic analysis of human blood specimens: 
comparison between plasma specimens and serum by differential peptide 
display Proteomics (2005) 5: 3414-3422. 
Taylor Florence A, Attwood D Physicochemical principles of pharmacy 
Pharmaceutical Press (2006) 4: 423. 
Todar K Immune defense against Bacterial pathogens: Innate Immunity Todar’s 
Online Textbook of Bacteriology (2008) www.textbookofbacteriology.net 
 116 
Tokunaga Y, Niidome T, Hatakeyama T, Aoyagi H, Antibacterial activity of 
bactenecin 5 fragments and their interaction with phospholipid membranes 
(2001) Pept Sci 7: 297-304. 
Tomasinsig L, Skerlavaj B, Papo N, Giabbai B, Shai Y, Zanetti M, Mechanistic and 
functional studies of the interaction of a proline-rich Antimicrobial peptide 
with mammalian cells J Biol Chem (2006) 281: 383-391.  
van Furth R, van Dissel JT Is the conventional doctrine about macrophage 
activation still true? FEMS Microbiol Immunol (1989) 5: 287-92. 
Truong K, Ikura M The use of FRET imaging microscopi to detect protein-
protein interactions and protein conformational changes in vivo Curr Opin 
Struct Biol  (2001) 11: 573-578. 
Tsutsumi Y, Onda M, Nagata S, Lee B, Kreitman RJ, Pastan I Site-specific 
chemical modification with polyethylene glycol of recombinant immunotoxin 
anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal 
toxicity and immunogenicity Proc Natl Acad Sci (2000) 97: 8548-8553. 
van’t Hof W, Veerman EC, Helmerhorst EJ, Amerongen AV Antimicrobial 
peptides: properties and applicability. J Biol Chem (2001) 382: 597- 619. 
Vazques-Torres A, Xu Y, Jones-Carson J, Holden D, Lucia S, Dinauer M, Mastroeni 
P, Fang F Salmonella Pathogenicity Island 2-dependent evasion of the phagocyte 
NADPH Oxidase Science (2000) 287: 1655-1658. 
Veronese F, Post-translational Modification of Protein Biopharmaceuticals 
(2009). 
Veronese FM, Mero A The impact of PEGylation on biological terapy BioDrugs 
(2008) 22: 315-329. 
Veronese F, Pasut G Pegylation, successful approach to drug delivery DDT 
(2005) 10: 1451-1458. 
Vives E, Schmidt J, Pelegrin A Cell-penetrating and cell-targeting peptides in 
drug delivery Biochim biophys Acta  (2008) 1786: 126-138. 
Yang RB, Mark MR, Gurney AL, Godowski PJ Signaling events induced by 
lipopolysaccharide-activated toll-like receptor 2. J Immunol (1999)163: 639–643. 
Yang D, Oppenheim J Antimicrobial proteins act as “alarmins” in joint immune 
defense Arthrititis and Rheumat (2004) 50: 3401-3403. 
Yeaman M, Bayer A Antimicrobial peptides from platelets Drug Resist Updat 
(1999) 2: 116-126. 
Yu X, McGourty K, Liu M, Unsworth K, Holden D. pH Sensing by Intracellular 
Salmonella Induces Effector Translocation. Science (2010) 328: 981-2. 
Wade D, Boman A, Wahlin B, Drain CM, Andreu D, Boman HG, Merrifield RB 
All-D amino acid-containing channel-forming antibiotic peptides Proc natl Acad 
Sci USA (1990) 87: 4761-4765. 
Waddell WJ A simple ultraviolet spectrometric method for the determination of 
protein J Lab Clin Med (1956) 48: 311-314. 
Warrel T, Cox J, Firth S The host response to infection The Oxford textbook of 
Medicine  Forth ed. (2003): 281-284. 
 117 
Watson K, Holden DW Dynamics of growth and dissemination of Salmonella in 
vivo Cell Microbiol (2010) 12: 1389-1397. 
Werle M, Bernkop-Schnurch A Strategies to improve plasma half life time of 
peptide and protein drugs Amino Acids (2006) 30: 351-367. 
Wijburg OL, Simmons CP, van Rooijen N, Strugnell RA Dual role for 
macrophages in vivo in pathogenesis and control of murine Salmonella enterica 
var. Typhimurium infections Eur J Immunol (2000) 30: 944-953. 
Zaiou M, Nizet V, Gallo RL Antimicrobial and protease inhibitory functions of 
the human cathelicidin (hCAP18/LL-37) prosequence. J Invest Dermatol (2003) 
120: 810- 816. 
Zanetti M, Gennaro R, Romeo D Cathelicidins: a novel protein family with a 
common proregion and a variable C-terminal antimicrobial domain FEBS Lett 
(1995) 374: 1-5. 
Zanetti M Cathelicidins, multifunctional peptides of the innate immunity J Leuk 
Biol (2004) 75: 39-48. 
Zanetti M, Litteri L, Gennaro R, Horstmann H, Romeo D, Bactenecins, defense 
polypeptides of bovine neutrophils, are generated from precursor  molecules 
stored in the large granules J Cell Biol (1990) 111: 1363-1371. 
Zerial A, Skerlavaj B, Gennaro R, Romeo D Inactivation of herpes simplex virus 
by protein components of bovine neutrophil granules Antiviral Res (1987) 6: 
2661-2667. 
Zerial A, Skerlavaj B, Gennaro R, Romeo D, Inactivation of herpes simplex virus 
by protein component of bovine neutrophil granules Antivir Res (1987) 7: 341-
352. 
Zhang W, Feng J, Harris Contag P, Stevenson D, Contag C Rapid in vivo 
functional analysis of transgenes in mice using whole body imaging of luciferase 
expression Transgen Res (2001) 10: 423-424. 
Zhang G, Han B, Lin X, Wu X, Yan H Modification of Antimicrobial Peptide 
with Low Molar Mass Poly(ethylene glycol) J Biochem (2008) 44: 781-788.  
 
